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Abstract of Dissertation 
 
 
 
MODULATION OF THE ADRENAL MEDULLARY RESPONSE TO 
STRESS BY ESTRADIOL IN THE FEMALE RAT 
 
The present study has established that physiological concentrations of estradiol can modulate 
stress-induced increases in plasma epinephrine (EPI).  In anesthetized female rats, insulin-
induced hypoglycemia (0.25 U/kg) increased plasma EPI concentration to a significantly greater 
extent in 14-day ovariectomized (OVEX) rats compared to sham-operated controls.  In 17β-
estradiol (E2)-replaced OVEX rats, the hypoglycemia-induced rise in plasma EPI was 
significantly reduced compared to OVEX rats.  This suppression was due to both decreased 
adrenal medullary output and increased clearance of EPI.    Adrenal venous EPI concentration 
was significantly reduced in OVEX+E2 rats, suggesting that EPI secretion from the adrenal 
medulla was decreased by E2 replacement.  The underlying mechanism(s) of this apparent E2-
mediated reduction in secretion could not be established since 1) the expression levels of the 
biosynthetic enzymes tyrosine hydroxylase and phenylethanolamine N-methyltransferase were 
not affected in OVEX+E2 rats, suggesting that EPI biosynthesis is similar in these and OVEX 
rats; and 2) agonist-induced increases in intracellular Ca P2+ Pwere identical in isolated adrenal 
medullary chromaffin cells exposed to E2 (10 nM) or vehicle for 48 hr, suggesting that stimulus 
secretion coupling is unaffected by E2 treatment.  In contrast, plasma clearance of EPI was 
significantly increased in OVEX+E2 rats.  
Although 48 hr exposure to E2 had no effect on intracellular signaling in chromaffin cells, 
acute (3 min) exposure to micromolar concentrations of E2 dose-dependently and reversibly 
inhibited agonist-induced Ca P2+ Ptransients. Consistent with this observation, acute (30 min) 
infusions of E2 also significantly reduced the insulin-induced increase in plasma EPI in OVEX 
rats.  These data demonstrate that physiological levels of circulating E2 can modulate 
hypoglycemia-induced increases in plasma EPI.  This effect appears to be mediated by the 
steroid’s influence on adrenal medullary EPI output and plasma EPI clearance; however the 
mechanism(s) underlying these E2-mediated modulations remain undetermined.  This study has 
also established that acute exposure to supra-physiological levels of E2 can suppress 
hypoglycemia-induced increases in plasma EPI, due at least in part to inhibition of stimulus-
secretion coupling.     
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Chapter 1:  Introduction 
 
Estrogen 
Estrogen and progesterone are the main steroid hormones synthesized by and 
secreted from the ovary.  Estradiol, the most biologically active form of estrogen, is 
produced by the granulosa cells of antral follicles and is responsible for various actions 
throughout the reproductive system.  For example, estradiol induces the proliferation of 
granulosa cells in the ovary, the epithelial and stromal layers in the uterus, and the 
epithelium in the vagina.  The development of the lactiferous duct system in the 
mammary glands is also dependent upon the presence of estradiol (Kacsoh, 2000).   
Typically, estradiol acts through traditional steroid receptor mechanisms.  
Intracellular estrogen receptors, which act as transcription factors, bind estradiol and 
dimerize in the cytoplasm of the target cell.  The estrogen receptor dimer translocates to 
the nucleus and binds estrogen-responsive elements located in the promoter region of 
estrogen-responsive genes, thereby regulating transcription of these genes.  There are 
at least two subtypes of estrogen receptors, the classic estrogen receptor alpha (ERα), 
and the more recently discovered estrogen receptor beta (ERβ).  Although ERα and 
ERβ share a high degree of sequence homology, they are the product of two different 
genes and exhibit tissue/cell-specific expression and action (Matthews and Gustafsson, 
2003 for review).  In addition to acting via this traditional, relatively slow-onset genomic 
transcription/translation signaling pathway, several studies have demonstrated that 
estrogens can also initiate rapid activation of G-protein-coupled receptor signaling 
systems, perhaps by binding to distinct pools of estrogen receptors which locate to 
caveolae regions of the plasma membrane (Hall et al., 2001; Nadal et al., 2001; Levin, 
2002).  For example, acute exposure to estradiol stimulates a rise in intracellular Ca P2+ P, 
and activates the protein-kinase A and protein-kinase C signaling pathways in female 
colon cells, while in smooth muscle cells and atrial/ventricular myocytes, short-term 
estradiol exposure attenuates voltage-dependent Ca P2+ P current (Levin 1999 for review; 
Kelly and Levin, 2001).   
 
 
 
Extra-Reproductive Effects of Estrogen 
Although primarily regarded as the female sex hormone, estradiol acts beyond 
the scope of the reproductive axis at various sites, including bone, liver, kidney, brain, 
heart, and vasculature.   For instance, estradiol induces elongation of bone, the closure 
of the epiphyseal plates, and prevents bone resorption.  This latter benefit on bone 
remodeling is lost at menopause, a time in normal female aging when estradiol 
secretion declines.  This permanent decrease in circulating estradiol concentration is 
often accompanied by increased osteoporosis and bone fragility in postmenopausal 
women (Lindsay, 1996).  Recent studies have shown that hormone replacement 
therapies, which include estrogens, can decrease the incidence and severity of 
osteoporosis in post-menopausal women (Lawrenson et al., 2005; Stevenson, 2005).   
Several studies have shown that a number of health problems confronted by 
older women can be linked to the deficiency of circulating estradiol after menopause.  
For example, increases in the prevalence of heart disease and the incidence and 
severity of hypertension in post-menopausal women are reduced by hormone 
replacement therapy (Kannel et al., 1976; Pines et al., 1996; Prevlevic et al., 1997; 
Wassertheil-Smoller et al., 2000).  The mechanisms underlying these benefits are quite 
diverse, and include estrogenic effects on lipid and lipoprotein metabolism and both 
vascular reactivity and growth (Prevlevic et al., 1997; Dubey et al., 2001, 2004; 
Mendelsohn et al., 2005).  Additionally, estradiol replacement also lessens the risk 
and/or delays the onset of neurodegenerative conditions such as Alzheimer’s disease 
(Henderson et al., 1996; Asthana et al., 1997; Kawas et al., 1997; Baum, 2005), and 
provides cognitive benefits (see Gleason et al., 2005 for review) in post-menopausal 
women.   
Not all data are consistent with the concept that estrogen is protective against 
these types of illnesses. While it is widely accepted that high doses of estradiol can be 
harmful, increasing the risk of breast cancer, venous thrombosis, stroke, and pulmonary 
embolism (Gillum et al., 2000), clinicians with the Women’s Health Initiative (WHI), a 
study which has enrolled more than 160,000 participants overall, reported in 2002 that 
post-menopausal women receiving lower dose hormone replacement therapy (a 
combination of estrogen and progesterone) also have a higher risk for heart disease, 
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stroke and blood clots compared to post-menopausal women receiving placebo 
treatment (Pradhan et al.)  In 2004, it was reported that post-menopausal women 
receiving estrogen-only therapy are also at a greater risk for blood clots, stroke and 
dementia than those in the placebo control group (Anderson et al.).  In light of these 
reports, doctors halted all hormone and estrogen-only treatment studies in the WHI.  It 
should be noted, however, that the estrogens used in these replacement therapies were 
conjugated equine estrogens, which can adversely affect the liver (Turgeon et al., 
2004), that the therapies were given orally, which can affect hemostasis (Scarabin et al., 
1997; Luyer et al., 2001), and that the women who were enrolled in these studies were 
well past the onset of menopause (average age of 63 and 65 years old) when they 
began the therapies.   Given these cohorts and the fact that the levels of estrogen 
administered orally in hormone and estrogen replacement therapies are typically non-
physiologic, even in low-dose regimes, the effects of physiologic levels of estradiol in 
younger individuals have remained undefined.   
Several basic science studies have investigated the effects of estradiol in more 
controlled paradigms.  Dubal and Wise (2001) have demonstrated that both estrous and 
pro-estrous concentrations of estradiol replacement in ovariectomized rats protects 
against infarct injury during ischemic stroke in both young and middle aged rats.  In 
these studies, estradiol protected against stroke-induced injury by inhibiting infarct-
induced cell death.  High doses of estradiol are also protective against ischemic brain 
injury, as demonstrated by Yang et al. (2000). In these studies, the injection of estradiol 
up to 3 hours after the initial injury attenuated infarct-induced damage by modulating 
both cerebral blood flow and the production of nitric oxide.   
Beneficial/protective effects of estradiol have also been demonstrated in the 
cardiovascular system.  Chronic estrogen treatment lowers blood pressure in both 
transgenic and spontaneously hypertensive rats (Brosnihan et al., 1997; Crofton and 
Share, 1997; Li et al., 1997).  Pressor responses to phenylephrine are also reduced in 
chronically estradiol-treated ovariectomized rats, while indices of baroreflex sensitivity 
are greater than in vehicle treated controls (He et al., 1998).  This latter conclusion is 
supported by a study in conscious mice, which demonstrated that estradiol facilitates 
baroreflex function, perhaps by modulating angiotensin II-mediated effects on the 
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cardiovascular system (Pamidimukkala et al., 2003). He et al. (1998) also demonstrated 
that an acute, intravenous injection of estradiol lowers heart rate, and renal and 
splanchnic nerve activity in ovariectomized rats compared to vehicle-treated controls.    
 
Estrogen and Stress  
Stress responses are affected by estradiol in a variety of manners.  For example, 
post-menopausal women have increased behavioral responses to mental stress 
compared to pre-menopausal women, and estrogen therapy attenuates this increase 
(Lindheim et al., 1992; Owens et al., 1993).  These conclusions are supported by 
studies in experimental animals, which have shown that physiological concentrations of 
estradiol reduce anxiety and depressive behavior in rats subjected to open field, 
elevated plus maze, and forced swim tests (Lunga and Herbert, 2004; Walf and Frye, 
2005).  The activity of the hypothalamic-pituitary-adrenal axis (HPA axis) is also 
modulated by the presence of estradiol. Clinical studies have shown that cortisol levels 
are significantly decreased after menopause and are restored with estrogen 
replacement therapy (Helgason et al., 1981).  In the rat, basal plasma levels of both 
ACTH and corticosterone are lower in ovariectomized rats than in intact controls and 
estradiol replacement returns both hormones to control levels (Burgess and Handa, 
1992, Seale et al., 2004, Lunga and Herbert, 2004, Serova et al., 2005).  In contrast, 
immobilization stress-induced increases in plasma ACTH concentrations are 
significantly lower in estradiol-replaced ovariectomized rats than in their controls 
(Serova et al., 2005).   
 
Adrenal Medullary Response to Stress 
As first proposed by Cannon in 1934, it is now well established that the adrenal 
gland is vital in the maintenance of overall body homeostasis during times of stress.  
Stressors such as trauma (Hammond et al., 1956; Barton et al, 1981), hypotension (Lilly 
et al., 1982; Bereiter et al., 1984), cold (Gordon et al., 1966; LeBlanc et al., 1967; 
Kanayama et al., 1999), hypoxia (Fowler et al., 1961; Bloom et al., 1977), and 
hypoglycemia (Niijma, 1989) result in a marked increase in both adrenal medullary 
catecholamine and adrenocortical glucocorticoid secretion, resulting in adaptation to the 
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stressor by eliciting diverse cardiovascular, metabolic, and immunomodulatory effects 
(Axelrod and Reisine, 1984; Becker, 1986; Ewbank 1992).  Furthermore, tolerance to 
such stressors as exercise (Winder et al., 1987), hemorrhage (Bond and Johnson, 
1984), and hypoxia (Nahas et al., 1954) is severely reduced in adrenalectomized and/or 
adrenal de-medullated animals.   
 The principal catecholamines, epinephrine (EPI) and norepinephrine (NE) are 
synthesized by and released from adrenal medullary chromaffin cells, which are 
considered functionally similar to postsynaptic sympathetic neurons.  However, these 
cells do not have axons, and therefore function in a more endocrine manner by 
secreting epinephrine and norepinephrine directly into the blood stream.  
Catecholamine biosynthesis occurs within the cells through a series of enzymatic 
reactions, with the conversion of tyrosine to dihydroxyphenylanine (DOPA) by tyrosine 
hydroxylase as the initial and rate-limiting step.  DOPA is then converted to dopamine 
(DA) by dopa decarboxylase (DDC) and DA is converted to NE by dopamine-beta-
hydroxylase (DBH).  Lastly, NE is converted to EPI by phenyl-ethanolamine-N-
methyltransferase (PNMT).   
It is well established that there are two separate populations of chromaffin cells 
(Moro et al., 1990) characterized by the presence or absence of this latter enzyme.  The 
ratio of PNMT containing (EPI secreting) cells to non-PNMT containing (NE secreting) 
cells is species dependent.  For example, the ratio of EPI secreting to NE secreting cells 
in the rat adrenal medulla is approximately 4:1 (Verhofstad et al., 1985; Tomlinson et 
al., 1987), while the ratio is approximately 1:1 in the pig (Verhofstad et al., 1989).  In 
humans, approximately 80% of adrenal medullary chromaffin cells are EPI secreting 
while just 20% are NE (Vollmer, 1996 for review).   
Catecholamines are stored in vesicles until their release, which occurs when a 
stress-induced increase in splanchnic nerve activity stimulates secretion from the 
chromaffin cell.  Mechanistically, acetylcholine, released from the adrenal nerve (a 
branch of the splanchnic nerve), induces sodium (Na+) and calcium (Ca2+) influx via 
nicotinic receptor-operated ion channels (Wada et al., 1985).  The resultant 
depolarization activates voltage gated Ca2+ channels and results in a transient rise in 
intracellular free Ca2+ concentration, which is the primary trigger for catecholamine 
 5
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exocytosis (Kilpatrick et al, 1982). The rise in intracellular Ca P2+ P can also increase the 
activity of tyrosine hydroxylase, the rate-limiting enzyme in the biosynthetic cascade and 
therefore enhance catecholamine biosynthesis, which allows chromaffin cells the ability 
to maintain catecholamine stores in cases of increased secretion and maintain the 
cellular catecholamine content at a relatively constant amount, a process described as 
stimulus-synthesis-secretion coupling (Wakade et al., 1988; Malhotra et al., 1989).  
 
Estradiol and the Adrenal Medullary Response to Stress 
While the response of the HPA axis to a stressor is usually enhanced by 
estradiol, clinical studies indicate that stress-induced increases in plasma 
catecholamines are lower in post-menopausal women receiving estrogen replacement 
therapy (Del Rio et al., 1993; Komesaroff et al., 1999; Ceresinsi et al., 2000; Sandoval 
et al., 2003). Despite these persuasive clinical observations, the mechanism(s) 
underlying this estrogen-dependent suppression of stress-evoked catecholamine 
responses, and more specifically the effects of normal circulating levels of estrogen on 
this response, have not been convincingly established.  Conclusions from studies in the 
rat are contradictory and may be dependent upon several factors, including the type of 
stressor utilized and the age, weight, and strain of the rat. For example, the 
hypoglycemia-induced increase in plasma catecholamine concentration is attenuated in 
female rats compared to weight-matched males (Drake et al., 1998), while foot-shock 
evoked increases are enhanced in females compared to age-matched males 
(Weinstock et al, 1998).   
The prospect that estradiol can affect adrenal medullary function is supported by 
a report which identified ERα immunoreactivity in chromaffin cells of the female but not 
male rat adrenal gland (Green et al., 1999).  However, information regarding estrogen 
effects on catecholamine biosynthesis is both limited and inconclusive. For example, it 
has been reported that daily injections of a high dose of estradiol for 3 days increases 
adrenal medullary epinephrine content in ovariectomized rats (Fernandez-Ruiz et al., 
1988), and that 10 days of estrogen treatment in intact female rats increases the activity 
of adrenal tyrosine hydroxylase (TH), the rate limiting enzyme in the biosynthetic 
cascade (Kohler et al., 1975).  In contrast, TH activity was reported to be unaffected by 
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estrogen treatment in ovariectomized rats (de Miguel et al., 1989).  More recently, 
Serova et al. (2005) have demonstrated that TH mRNA levels are increased in the 
adrenal medulla of non-stressed, estradiol-treated ovariectomized rats compared to 
vehicle-treated controls.  Conversely, the treatment paradigm utilized in this study also 
inhibited the stress-induced increase in TH mRNA levels seen in the control group.  
It is now accepted that in addition to acting via traditional steroid-receptor 
signaling pathways, members of the steroid receptor superfamily, can rapidly affect cell 
function (Losel et al., 2003 for review).  Previous studies from our laboratory have 
identified crosstalk between the adrenal stress hormones, establishing that both acute 
and long-term exposure to physiologic concentrations of glucocorticoids can modulate 
catecholamine stimulus-secretion pathways in vitro in both rat and pig chromaffin cells.  
Notably, these effects were found to be diametrically opposite: long-term exposure to 
physiologic concentrations of the synthetic glucocorticoid dexamethasone potentiates 
voltage-gated CaP2+ P channel current, consequently potentiating  agonist-induced 
intracellular Ca P2+ P transients (Fuller et al., 1997a,b),  while acute exposure to 
dexamethasone dose-dependently attenuates voltage-gated Ca P2+ P channel current and 
the subsequent intracellular Ca P2+ P transient (Wagner et al., 1999).   
Several in vitro studies have demonstrated that relatively high concentrations of 
estrogen can also acutely and therefore, presumably non-genomically, modulate 
adrenal medullary function. For example, in the isolated perfused rat adrenal gland, 
nicotinic agonist-induced catecholamine secretion is suppressed within minutes of 
exposure to 17α-estradiol (Park et al., 1996). Similarly, short-term exposure to 17α-
estradiol suppresses secretory responses to both nicotinic agonists and to direct 
depolarization with KCl in isolated perfused bovine and feline adrenal glands (Lopez et 
al., 1991). Mechanistically, the KCl data combined with the fact that steroid treatment 
also suppresses agonist-induced P45 PCaP2+ P uptake in isolated bovine chromaffin cells, 
suggests that the primary site of estradiol action may be the voltage-gated Ca P2+ P 
channel. Consistent with this concept, Kim et al., (2000) have demonstrated that short-
term exposure to 17β-estradiol suppresses KCl-induced [ P3 PH] nor-epinephrine secretion 
and intracellular Ca P2+ P transients in the PC-12 cell line, an established model of the 
medullary chromaffin cell. At least in this model, channel-selective antagonist studies 
 
demonstrated that estrogen inhibited both L- and N-type voltage-gated Ca2+ channels.  
Evidence in favor of an acute suppressive effect of estradiol on catecholamine secretion 
in vitro is not unanimous however. Dar and Zinder (1997) have reported that, compared 
to the effects of progestins and androgens, estrogens in general have relatively little 
effect on agonist-induced catecholamine secretion in bovine chromaffin cells.  While the 
rapid-onset effects of estradiol on catecholamine secretion described above are 
consistent with a non-genomic mechanism of hormone action, it is not clear whether the 
effects have physiological significance, since the concentrations of steroid used in all of 
the these studies far exceeds normal plasma levels of estrogen in the rat (Smith et al., 
1975).  
Based on these data that non-physiological levels of estrogen can modulate the 
adrenal medullary response to stress in post-menopausal women and that acute 
exposure to high levels of estradiol can affect stimulus-secretion coupling in the 
chromaffin cell, the primary goal of the studies presented in this dissertation was to 
specifically determine whether physiological levels of estradiol can affect stress-induced 
increases in plasma catecholamine concentration.  The working hypothesis to be tested 
was that physiological concentrations of estradiol attenuate the stress-induced 
increase in plasma epinephrine concentration by directly suppressing secretion 
from the adrenal medullary chromaffin cell.  
 
 
 
 
 
 
 
 
 
 
 
Copyright © Julye M. Adams 2005 
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Chapter 2:  Materials and Methods 
 
Animals and Experimental Treatments  
All animal protocols were approved by the University of Kentucky Institutional 
Animal Care and Use Committee and utilized 12-14 week-old female Sprague-Dawley 
rats.  Animals were housed individually in a room with controlled temperature (24 Po PC) 
and light (14:10-h light-dark cycle) and given free access to food and water.  Bilateral 
ovariectomy (or sham-surgery) was performed under isoflurane anesthesia via two 
small flank incisions.  For estradiol replacement, capsules containing either 17β-
estradiol or vehicle were implanted subcutaneously at this time. The implanted capsules 
were made in accordance with previously published protocols (Wise et al., 1981; Dubal 
et al., 2001), by injecting 0.07 mL of either 17β-estradiol (1 mg/mL; Sigma; St. Louis, 
MO) or sesame oil into 30 mm lengths of SILASTIC brand tubing (0.062/0.125 in 
inner/outer diameter; Dow Corning; Midland, MI).  Each capsule was capped at both 
ends with 5 mm wooden applicator sticks.   
  Uterine weight and the change in overall body weight 14 days after surgery are 
listed in Table 2.1.  Plasma estradiol concentrations measured 14 days after surgery are 
displayed in Figure 2.1.  Ovariectomized rats gained more overall body weight and had 
significantly lower uterine weights and plasma estradiol concentrations than the sham-
operated controls. Uterine weights and plasma estradiol concentrations were 
significantly greater and changes in body weight were significantly reduced in the 
estradiol-replaced group compared to the ovariectomized group.  Estradiol replacement 
produced plasma estradiol concentrations equivalent to those of sham rats during the 
proestrous phase of the estrous cycle.  Uterine weights and changes in body weight 
also were not different between these two groups.   
 
In Vivo Studies 
The primary catecholamine secreted from the adrenal medulla is epinephrine 
(EPI; Vollmer, 1996).  Therefore, plasma EPI concentrations in response to stress were 
determined in all treatment groups.   
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Insulin-induced hypoglycemia was used as a stressor to assess the effects of 
estradiol on increases in plasma EPI. This well established paradigm elicits consistent 
increases in plasma EPI levels in both experimental animals (Vollmer et al., 1997; 
Drake et al., 1998) and humans (Diamond et al., 1993; Davis et al., 2000).   
 
A.  Hypoglycemic-Stress Model  
1.  Measurement of Stress-Induced Plasma Epinephrine Concentrations 
For these experiments, overnight-fasted rats were anesthetized with inactin (100 
mg/kg, i.p.; Sigma) and following tracheotomy, the left femoral artery and femoral vein 
were catheterized with PE 50 tubing. Core body temperature was maintained at 36.7Po PC 
by heat pad/lamp, and blood pressure and heart rate were recorded with a Grass Model 
7 polygraph (Grass Instruments Co.; Quincy , MA) for the duration of the experiment.  
After a 30 min equilibration period, a baseline arterial blood sample (0.6 mL) was taken 
and a bolus of insulin was injected via the femoral vein (Figure 2.2). Additional blood 
samples were taken 30 and 60 min post-insulin. Blood volume was replaced with 0.9% 
sterile saline. A small volume (10 µL) from each heparinized sample was used to 
measure blood glucose concentrations by a OneTouch Ultra glucose monitoring system 
(glucometer; Lifescan-Johnson & Johnson; Milpitas, CA), and the sample was 
centrifuged and the plasma was stored at -80 Po PC for later EPI analysis by enzyme-linked 
immunosorbent assay (ELISA).  Preliminary experiments established that blood-
sampling performed in the absence of insulin-induced hypoglycemia did not increase 
plasma epinephrine concentration above baseline (Figure 2.3).  
Preliminary experiments also examined the effects of two concentrations of 
insulin on plasma EPI concentration.  Both 0.25 U/kg and 1.0 U/kg of insulin elicited 
decreases in plasma glucose concentrations (∆ -67 ± 2.1% and >-76 ± 1.2%, 
respectively) and increases in plasma EPI concentrations (5 fold and 30 fold, 
respectively) after 30 min of hypoglycemia. (It should be noted that, in several rats, 1.0 
U/kg of insulin lowered plasma glucose to below the detectable range (< 20 mg/dL) of 
the glucometer after 30 min of hypoglycemia.)   Both the decrease in plasma glucose 
and the increase in plasma EPI concentrations were significantly greater in the 1.0 U/kg 
insulin-treated compared to the 0.25 U/kg insulin treated rats (Figure 2.4; P<0.01).  After 
 
60 min, plasma glucose and EPI concentrations returned toward baseline in 0.25 U/kg 
insulin-treated rats.  Glucose and EPI concentrations in the 1.0 U/kg insulin-treated rats 
did not differ after 60 min of hypoglycemia compared to 30 min, and were significantly 
different than the 0.25 U/kg insulin-treated group at 60 min (P<0.01).  All subsequent 
experiments utilized the sub-maximal stress effects of the 0.25 U/kg dose of insulin to 
determine the effects of estradiol on hypoglycemia-induced increases in plasma EPI 
concentration.  
 
2.  Measurement of Adrenal Medullary Epinephrine Output 
For these experiments, a method for the collection of adrenal venous blood 
previously published by Vollmer et al. (2000) was modified for use with the basic 
hypoglycemia protocol.  After the femoral cannulations, a peritoneal incision was made 
and the abdominal wall retracted to reveal the left kidney, adrenal gland, and 
surrounding vasculature.  Ligatures were tightened around the renal vein and artery just 
proximal to the hilus of the kidney.  A loose (non-tightened) ligature was placed around 
the renal vein just distal to the vena-cava.  Visible venous branches were either ligated 
or cauterized so that only adrenal venous flow entered the renal vein.   A bolus dose of 
heparin (300 U/kg) was injected intravenously and a small length (9-10 mm) of capped 
PE 50 tubing filled with heparinized saline was placed in the renal vein distal to the 
adrenal vein branch.  Insulin was injected after a 30 min equilibration period.  After 24 
min of hypoglycemia, the loose ligature at the vena cava was tightened and 
renal/adrenal venous flow was allowed to backflow through the uncapped renal vein 
catheter and was collected in a pre-weighed 1.5 mL microcentrifuge tube.  The 
collection continued for 6 min and was weighed to quantify a flow rate which was used 
to determine the adrenal medullary secretion rate.  No arterial blood samples were 
taken during these experiments.   
 
3.  Measurement of Sympathetic Nerve Activity (SNA) 
The basic hypoglycemia model was modified in order to record renal nerve 
activity in accordance with previously published methods (Randall et al., 1994; Brown et 
al., 1999; Stocker et al., 2004).  After the femoral cannulations, a retroperitoneal incision 
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was made and the left kidney was retracted allowing the isolation of a sympathetic renal 
nerve.  After placing the nerve on a stainless steel wire electrode and covering both the 
nerve and wire with a silicon-based impression material (Super-Dent Light, Darby 
Dental Supply; Westbury, NY), the electrical signals from the nerve were obtained using 
a high-impedance probe and were amplified (50,000) and band-pass filtered (between 
30-3,000 Hz) by a Grass P511 differential amplifier.  The data were digitized at 10,000 
samples/sec using a Cache 486 microprocessor and Data Translation DT2821-F 
analog-to-digital converter.  Nerve signals were recorded for 20 min before and 60 min 
after an insulin bolus.  The raw nerve signal was full-wave rectified and integrated (1 
sec time constant) using software developed by Dr. David Brown in Visual C++ (Figure 
2.5).  Background noise was determined by the average value of integrated voltage 
over 5 min after a bolus injection of 1M KCl (3 mL/kg; i.v.) to euthanatize the rat.  No 
arterial blood samples were taken during these experiments.  
Values for renal sympathetic nerve activity were measured as 1 min averages 
every 5 min after the insulin bolus.  This activity was expressed as a percent change 
from an average baseline value that was calculated from 3 separate 1 min averages 10, 
5, and 1 min before insulin.  Background noise was subtracted from all 1 min averages 
prior to calculating the percent change.   
 
B.  Measurement of Epinephrine Clearance  
For these experiments, methods from Azoui et al. (1997) and Marker et al. (1998) 
were modified (Figure 2.6) and rats were infused with 3 increasing doses of EPI for 30 
min each, equaling a total infusion time of 90 min.  Rats were anesthetized with inactin 
(100 mg/kg, i.p.) and following tracheotomy, the left femoral artery and left and right 
femoral veins were catheterized with PE 50 tubing. Core body temperature was 
maintained at 36.7oC by heat pad/lamp and blood pressure and heart rate were 
recorded with a Grass Model 7 polygraph for the duration of the experiment.  After a 30 
min equilibration period, a baseline arterial blood sample (0.6 mL) was taken and an 
intravenous infusion of EPI (Sigma) was started at a rate of 600 pmol/kg/min.  After 30 
min of infusion, an arterial blood sample (0.6 mL) was taken and the EPI infusion rate 
was increased to 1500 pmol/kg/min by change-out of the syringe on the infusion pump.  
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This ensured that the infused volume over 30 min remained consistent for all doses.  An 
arterial blood sample was taken after 30 min and the EPI infusion rate was increased to 
3000 pmol/kg/min.  The last blood sample was taken 30 min later. Each heparinized 
blood sample was centrifuged and plasma was stored at -80oC for later catecholamine 
analysis by ELISA.   
 
In Vitro Studies 
A.  Rat Adrenal Medullary Chromaffin Cells 
1.  Chromaffin Cell Isolation  
Chromaffin cells were isolated from the adrenal medullae of 12-14 week-old 
female Sprague-Dawley rats as previously described by Fuller et al. (1997a).  Adrenal 
glands were removed from CO2-euthanatized rats and submerged in warmed (37oC) 
Hank’s balanced salt solution (HBSS 7.4). The adrenal medullae were dissected from 
the cortical tissue and cut into four pieces and washed in HBSS.  The tissue was then 
suspended in Ca2+/Mg2+-free HBSS containing 0.3% collagenase D, 0.15% 
hyaluronidase, and 0.02% DNase, and transferred to a spinner flask for digestion.  The 
medullae pieces were incubated at 37oC for approximately 30 min with gentle spinning 
and with trituration by a fire polished glass pipette every 10 min to break up chunks of 
tissue.  The suspension was checked several times during the digestion for single cells, 
30 min generally yielded a majority of healthy single cells.  The cell suspension was 
then filtered through a 200 µM screen into a 15 mL centrifuge tube and the cells were 
washed in enzyme-free, Ca2+/Mg2+-free HBSS and centrifuged at 1500 rpm for 3 min.  
The cells were resuspended in DMEM containing 10% fetal bovine serum, 40 mg/L 
gentamicin, 100,000 U/L penicillin, 40,000 U/L nystatin, 4 g/L ascorbate, and 10 µM 
cytosine arabinose.  Aliquots of the cell suspension were allowed to adhere to poly-L-
lysine coated glass cover slips in 6-well plates for 30 min in a 37oC incubator, after 
which 0.5 mL of culture medium was added to the wells and the cells maintained in a 
humidified, 37oC environment of 5% CO2. Culture medium was changed 24 hr after 
plating, and cells were used 48 hr after isolation. 
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2.  Intracellular Calcium Measurements 
Intracellular Ca2+ transients were analyzed using established protocols as 
previously described (Liu et al., 2001; Jorgensen et al., 2002).  In each experiment, 
cytosolic Ca2+ was measured simultaneously in 5-12 chromaffin cells loaded with the 
fluorescent dye fura-2 using a dual-excitation spectrofluorometric system (Zeiss 
AttoFluor Ratio Vision Workstation, Atto Instruments, Inc.; Rockville, MD).  Before 
experimental analysis, the cells were rinsed 3X with HBSS and loaded with 5 µM fura-
2AM plus 0.1% Pluronic F-127 for 45 min at 37oC.  After this time, the cells were rinsed 
again with HBSS and allowed to recover for at least 15 min.  The cover slip was 
mounted in a closed perfusion chamber (Warner Instrument Corp.; Hamden, CT), 
placed on the stage of a Zeiss Axiovert inverted microscope fitted with a 40X 
fluorescence oil immersion objective, and constantly perfused by gravity-feed with 
ambient temperature HBSS at 1-3 mL/min. 
For these experiments, non-stimulated (basal) fluorescence was measured for 
approximately 30 sec, an agonist was added by a rapid change-out of the bathing 
medium, and was removed after 15 sec by a second bath change-out.  There was a 10 
min recovery period before each re-stimulation.  Fluorescence was determined using 
excitation wavelengths of 340 nm and 380 nm and an emission wavelength of 510 nm.  
Ratiometric data were collected and converted to cytosolic Ca2+ ([Ca2+]i) estimates 
based on a curve generated using a two-point calibration method and the following 
equation (Grynkiewicz et al., 1995): 
 [Ca2+]i = Kd [(R – R(min) / R(max) – R)] X [Den(min)/Den(max)] 
where R = measured ratio; Kd = dissociation constant for the dye; R(min) = ratio 
for the low standard (Ca2+ -free solution); R(max) = ratio for high standard (10 
mM Ca2+ solution); Den(min) = denominator intensity for the low standard; Den 
(max) = denominator intensity for the high standard. 
 
B.  NCI-H295R cells 
1.  Cell Culture  
An aliquot of the adrenal cortical cell line NCI-H295R was obtained from 
American Type Culture Collection (ATCC; Manasssas, VA) and the cells were grown 
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according to the product information sheet supplied.  Cells were maintained in complete 
growth medium containing a 1:1 mixture of Dulbecco’s Modified Eagle’s Medium and 
Ham’s F12 medium + L-glutamine (2.5 mM), HEPES (15 mM), sodium pyruvate (0.5 
mM), and sodium bicarbonate (1.2 g/L) , supplemented with 2.5% Nu-Serum (BD 
Biosciences) and the additives insulin (6.25 µg/mL), transferrin (6.25 µg/mL), selenium 
(6.25 µg/mL), bovine serum albumin (1.25 mg/mL), and linoleic acid (5.35 µg/mL) in a 
humidified,  37oC environment with 5% CO2.  Cells were subcultured weekly at a ratio of 
1:4 using a solution of 0.25% Trypsin-EDTA. 
 
2.  cAMP Accumulation 
Incubations were conducted on H295R cells in 24-well plates (200,000 
cells/well).  The well plates were placed in a 37oC water bath and the culture medium 
removed and replaced with warmed pre-incubation medium (0.25 mL)  consisting of 
Eagle’s Balanced Salt Solution (EBSS, pH 7.4) supplemented with the cAMP 
phosphodiesterase inhibitor Ro20-1724 (25 µM; Calbiochem; La Jolla, CA).  After 10 
min of pre-incubation, warmed incubation medium (0.25 mL) containing either vehicle or 
agonist in pre-incubation medium was added to the wells.  The medium was removed 
after 10 minutes of incubation and 0.25 mL of HCl (0.01 M) was added to the wells.  For 
protein analysis, 5% SDS (0.3 mL) was added in place of HCl to at least 4 wells from 
every experimental plate.  The plates were stored at -80oC for later analysis by enzyme 
immunoassay (EIA). 
 
Analytical Techniques 
A.  Plasma Epinephrine ELISA 
Plasma concentration of free EPI was determined by a non-competitive, 
monoamine specific ELISA kit (KMI-IBL; Hamburg, Germany).  EPI was extracted from 
kit standards, kit controls and plasma samples (0.25 mL) and was chemically converted 
to biotin derivatives.  Basal samples were diluted 1:2, 30 min and 60 min samples were 
diluted 1:5 with HCl provided in the kit.  Standards, controls and diluted samples (0.05 
mL) were added in duplicate to the antigen-coated wells of a 96-well plate and the 
extracted EPI was enzymatically methylated and bound to antigens for N-
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acylmetanephrine.  After a wash step, the wells were incubated in a solution of anti-
biotin antibodies conjugated with alkaline phosphatase for 90 min, followed by second 
wash step.  The sandwich complex fixed to the wells was visualized with a signal 
amplification system, which utilizes NADPH as the substrate for alkaline phosphatase 
and allows the conversion of p-iodonitrotetrazolium (colorless) to formazan (hot 
pink/red).  The reaction was stopped after 15 min by the addition of H2PO4 and the 
developed color intensity was measured at 490 nm (reference wavelength 600-650 nm) 
within 1 hr using a 96-well plate reader (µQuant, Bio-Tek Inc; Winooski, VT).  All 
incubation steps required constant shaking (400-600 rpm) and were performed at room 
temperature.  It was essential for assay precision that the washes utilize an auto strip 
washer (ELx50, Bio-Tek).  Concentrations of samples were determined with the aid of 
KC-4 software (Bio-Tek), which interpolated the mean measured absorbancies against 
the standard curve (Figure 2.7) on each plate.  All comparisons were intra assay and 
the coefficient of variation (c.v.) was 9.8 ±1%.  
 
B.  Measurement of Plasma Estradiol Concentration 
1.  Estradiol Extraction 
Estradiol was extracted from rat plasma samples prior to assay by diethyl ether 
extraction.  Samples (0.2 mL) and diethyl ether (3 mL) were added to 16X125 mm 
vortex tubes in duplicate and tightly capped.  Samples were vigorously vortexed for 5 
min and the aqueous layer was frozen in an ethanol/dry ice bath.  The ether 
supernatant was decanted into 12X75 mm tubes, the ether evaporated and the tubes 
completely dried.  This process was accelerated by heating the samples to 40oC and 
placing under a vacuum.  The tubes were rinsed with ether and dried three additional 
times to ensure that the extracted estradiol accumulated at the bottom of the tube.  A 
set of clean 12X75 mm tubes used as standard and control assay tubes were washed 
with ether and dried at the same time as the samples. 
 
2.  Estradiol RadioImmunoAssay 
Plasma concentration of free estradiol was determined by an estradiol-specific 
RIA kit (DSL; Webster, TX).  After the final wash down and evaporation step of the 
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extraction, the samples were reconstituted in 0.2 mL of the zero standard from the kit 
and the appropriate volumes of kit-provided standards or controls were added to the 
ether washed, empty tubes.   Tubes (except the total count and non-specific binding) 
were incubated with estradiol-antiserum (4 hr, 4oC), and I-125 labeled estradiol was 
added to all assay tubes and the tubes incubated again at 4oC for 20-24 hr.  Tubes 
(except total count) were then incubated with precipitating reagent for 20 min at room 
temperature, centrifuged for 15 min at 1500 X g, decanted, and the iodinated estradiol 
contained in all tubes was measured for 1 min by gamma counter.  The percent ratio of 
the bound fraction of labeled estradiol in each sample (B) to that in the absence of 
unlabelled estradiol (Bmax) was calculated and interpolated against the standard curve 
to determine sample concentrations (Figure 2.8).  Control samples were assayed both 
in extracted and non-extracted form. 
 
C.  cAMP EIA 
Accumulated cAMP in the H295R cells was determined by a competitive EIA kit 
(Cayman Chemical; Ann Arbor, MI).  First, the experimental well plates were thawed 
and scraped to ensure total cell lysis and release of cAMP into the HCl.  The samples 
were then transferred to 1.5 mL microcentrifuge tubes and centrifuged at 1,000 X g for 
10 min.  Standards, controls, and samples were acetylated in 12X75 mm tubes and 
0.05 mL of each was added in duplicate to anti-rabbit IgG coated wells of a 96-well 
plate.  cAMP acetylcholinesterase (Tracer) and cAMP antiserum were added to the 
appropriate wells and the plate was incubated 18-24 hrs at 4oC.  The wells were 
washed using a plate washer (ELx50, Bio-Tek) and incubated in the dark with shaking 
(400-600 rpm) for 2 hrs at 25oC with the acetylchotinesterase (AChE) substrate 
(designated as Ellman’s reagent).  The intensity of the color (yellow) that developed was 
measured at 420 nM and was inversely proportional to the amount of free cAMP 
present.  The percent ratio of the AChE- labeled cAMP in the sample bound to the 
antibody (B) to the maximum capacity of the antibody for AChE-labeled cAMP in the 
absence of unlabelled cAMP (Bmax) was calculated and interpolated against the 
standard curve (Figure 2.9) to determine sample concentrations. 
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D.  Adrenal Medullary Gene Expression 
1. RNA isolation 
Adrenal medullary tissue was dissected from the adrenal glands of rats in the 
three treatment paradigms and was stored in RNAlater (Ambion; Houston, TX) at -20Po PC 
prior to RNA isolation.  Total RNA was extracted using an RNeasy Mini Kit (Quiagen; 
Valencia, CA).  Tissue was homogenized in a guanidine isothiocyanate-containing 
buffer with a Duall tissue grinder (Fisher Scientific; Pittsburg, PA).  The samples were 
centrifuged at 12,000 X g for 3 min and the supernatant was transferred to 1.5 mL 
microcentrifuge tubes.  One volume of ethanol (70%) was added to all samples and the 
solution applied to an RNeasy mini column containing a silica-gel membrane.  The 
columns were centrifuged for 15 sec at 8,000 X g and the flow-through discarded.  After 
an on-column DNase digestion and two high-salt washes, the total RNA was eluted 
from the column membrane with 0.03 mL of nanopure water and quantified 
spectrometrically at 260 nM. 
 
2. Reverse Transcription 
Single- stranded cDNA was synthesized from 1 µg of RNA using a Thermoscript 
RT kit (Invitrogen Life Technologies; Carlsbad, CA) and a protocol previously described 
(Carrithers et al., 2000).  The samples were incubated for 5 min at 65Po PC with random 
hexamers (final concentration of 5 µM) and dNTPs (final concentration of 1 mM) and 
immediately placed on ice.  RT components were added as a master mix containing (in 
final concentrations):  1X cDNA synthesis buffer (25 mM Tris acetate (pH 8.4), 75 mM 
potassium acetate, 8mM magnesium acetate); 0.75 U Thermoscript reverse 
transcriptase; 5 mM DTT; 2U RNase OUT.  Samples were incubated at 25Po PC for 10 min, 
55Po PC for 60 min, and 85 Po PC for 5 min.  RNase H (1 µL) was added to each reaction and 
incubated at 37 Po PC for 20 min to degrade existing RNA molecules.   The cDNA synthesis 
reactions were stored at -20Po PC or used immediately for polymerase chain reaction. 
 
3.  Polymerase chain reaction (PCR) 
An initial PCR reaction determined the amount of β-actin generated by 1 µL of 
each RT reaction at 26 cycles.  Subsequent PCR reactions were prepared with volumes 
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of RT reaction which were estimated (by CDD camera) to generate equal amounts of β-
actin.  The 50 µL PCR reaction mixture consisted of (in final concentrations): cDNA 
template (~ 5% of RT reaction); 20 mM Tris-HCl (pH 8.0); 50 mM KCl; 0.2 mM dNTPs; 
0.4 µM primers; 2 mM MgCl B2 B and 2.5 U of Platinum Taq Polymerase (Invitrogen Life 
Technologies).  PCR reactions utilized a Perkin Elmer GeneAmp PCR system 2400 
(Applied Biosystems; Foster City, CA).  Control reactions were performed in the 
absence of cDNA.  Samples (20% of reaction volume) were size fractionated by 3% 
agarose gel electrophoresis.  Ethidium bromide stained DNA bands were visualized by 
a UV Foto/analyst image analysis system equipped with a convertible dual 
transilluminator (Fotodyne; Hartland, WI).  The signal intensity of each PCR product 
was determined by an electronic imaging and analysis system with a CCD video 
camera (Fotodyne) and analyzed by UN-SCAN-IT software (Silk Scientific Inc; Orem, 
UT).  The primer sequences and cycle protocols for tyrosine hydroxylase (TH; Murru et 
al., 1997), phenylethanolamine N-methyltransferase (PNMT; Morita et al., 2001), 
estrogen receptor α (ERα; Kuiper et al., 1997), estrogen receptor β (ERβ; Byers et al., 
1997), and β-actin (Carrithers et al., 2000) have been previously published and are 
listed in Table 2.2. 
 
E.  Adrenal Medullary Protein Expression 
1.  Protein Isolation 
Adrenal medullary tissue was dissected from the adrenal glands of 
ovariectomized, vehicle and estradiol-treated rats and stored at -80 Po PC prior to protein 
isolation.   Samples were homogenized in a lysis buffer (pH 6.4) consisting of 25mM 
MES, 0.15mM NaCl, 1% TritonX-100, and 60mM n-octyl-β-D-glucopyranoside, stored 
on ice for 15 min, centrifuged (14,000g) at 4Po PC for 10 min.  The supernate was collected 
and stored at -20 Po PC.  Prior to use, P P5X protein sample buffer (pH 6.8) consisting of 0.31M 
Tris, 2.5% (w/v) SDS, 50% glycerol and 0.125% bromophenol blue was added to a final 
concentration of 1X.  All samples were heated to 95Po PC immediately prior to loading.   
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2.  Immunoblot 
Proteins were separated on a 12.5% polyacrylamide gel at 50mA (constant 
current) and subsequently transferred to PVDF membrane (0.45µM; Sigma) at 50V 
(constant voltage) for 2 hours.  Membranes were blocked with blotting buffer consisting 
of TBS plus 0.5% Tween 20 and 5% dry milk for 1 hr at 22P o PC.  Primary antibodies for 
ERα (Upstate Biotechnology; Lake Placid, NY), TH (BD Transduction Labs; San Jose, 
CA), and PNMT (Dia Sorin Inc; Stillwater, MN) were diluted in blotting buffer and 
incubated with blocked membranes for 1-24 hrs at 22Po PC.  Membranes were washed four 
times for 5 min in a buffer containing TBS plus 0.5% Tween 20 and 0.2% dry milk.  
Horseradish peroxidase conjugated IgGs directed against the appropriate host IgG were 
diluted and incubated with membranes for up to 1 hr.  Membranes were washed four 
times and visualized using chemiluminescence.  The relative signal intensities were 
determined densitometrically.  Equality of protein loading was determined qualitatively 
by Ponceau S staining of membranes.   
 
F.  Protein Concentration Analysis  
Protein concentrations of H295R cells and adrenal medullary tissue samples 
were determined by the colorimetric DC Protein Assay (Bio Rad; Hercules, CA).  This 
technique is similar to Lowry protein analysis.  Samples were thawed, triturated and 
0.05 mL was added in duplicate to 12 X 75 mm tubes as were bovine serum albumin 
standards (in 5% SDS, [0, 2.5, 5, 10, 25, and 50 mg/mL]).  A working solution of 0.02 
mL Reagent S per 1 mL Reagent A (alkaline copper tartrate solution) was made and 0.2 
mL added to all tubes along with 1.5 mL of Reagent B (dilute Folin solution).  All tubes 
were vortexed vigorously and the color (blue) developed for 15 min at 25 Po PC.  
Absorbance was measured at 550 nM.    
 
G.  Statistical Analysis 
Results are expressed as Mean ± SEM.  Statistical significance was determined 
using a t-test, paired t-test or ANOVA as appropriate.  Post-hoc analysis to compare 
multiple treatment groups utilized the Student-Newman-Keuls test.  Significance level 
was set at P<0.05. 
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  Uterine Weight (mg/mm)  ∆ Body Weight (g)   
  2 Weeks After Surgery 2 Weeks After Surgery 
SHAM 123 ± 9.5 -1.5 ± 5.6 
OVEX 50 ± 8.6* +39 ± 1.5*  
OVEX +E2 110 ± 7.4** -8 ± 0.9** 
 
 
 
 
 
Table 2.1 
 
Effect of Ovariectomy and Estradiol-Replacement in Ovariectomized Rats on Uterine 
Weight and Total Body Weight 
 
 
Uterine weight and changes in body weight 14 days after sham-surgery (SHAM), 
ovariectomy (OVEX), or ovariectomy + E2 replacement (OVEX +E2).  Values are Mean 
± SEM of data from 5 separate experiments.  * P< 0.01 compared to the SHAM group.  
** P< 0.05 compared to the OVEX group. 
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Figure 2.1 
 
Plasma Estradiol Concentrations 
 
 
Plasma estradiol concentrations were measured 14 days after ovariectomy (OVEX), or 
ovariectomy + E2 replacement (OVEX +E2).  Plasma estradiol concentration was 
measured 12-16 days after surgery in the sham-operated controls (SHAM) on the pro-
estrous day of the estrous cycle.  Columns represent Mean ± SEM of data from 5 
separate experiments.  * P< 0.01 compared to the SHAM group.  ** P< 0.01 compared 
to the OVEX group. 
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Figure 2.2 
 
Summary of the Insulin-Induced Hypoglycemia Paradigm 
 
 
OVEX: ovariectomy; E2: 17β-estradiol 
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Figure 2.3 
 
Effects of the Blood-Sampling Protocol on  
Epinephrine Concentrations 
 
 
Plasma glucose and epinephrine (EPI) concentrations in sham-operated rats during the 
hypoglycemic-stress paradigm blood sampling protocol in the absence of insulin.  
Vehicle (saline; 100 µL) was administered intravenously as a bolus at time 0. Arterial 
blood samples (0.6 mL) were taken immediately prior to and 30 and 60 minutes after 
the vehicle.  Upper Panel:  Plasma glucose concentrations.  Lower Panel:  Plasma EPI 
concentrations. Circles (upper panel) and columns (lower panel) represent Mean ± SEM 
of data from 4-5 separate experiments. 
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Figure 2.4 
 
Effect of 0.25 U/kg and 1.0 U/kg Insulin Bolus on Plasma Glucose and Epinephrine 
Concentrations 
 
 
Experiments were conducted 14 days after sham-surgery.   Insulin (0.25 U/kg or 1.0 
U/kg) was administered intravenously as a bolus at time 0. Arterial blood samples (0.6 
mL) were taken immediately prior to and 30 and 60 minutes after the insulin.  Upper 
Panel:  Plasma glucose concentrations. Lower Panel:  Plasma epinephrine (EPI) 
concentrations. Circles (upper panel) and columns (lower panel) represent Mean ± SEM 
of data from 6-8 separate experiments. * P< 0.01 compared to the 0.25 U/kg treated 
group. 
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Figure 2.5 
 
Typical Renal Sympathetic Nerve Recording 
 
 
Upper Panel:  Raw nerve activity over 60 milliseconds.  Middle Panel:  Rectified nerve 
activity over 60 milliseconds.  Lower Panel:  Rectified nerve activity integrated over 0.01 
second integrals for 10 seconds. 
 32
 
 33
 
 34
 
Figure 2.6 
 
Protocol for Measurement of Plasma Epinephrine Clearance 
 
 
OVEX: ovariectomy; E2: 17β-estradiol; EPI: epinephrine 
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Figure 2.7 
 
Representative Standard Curve Used for the  
Determination of Epinephrine Concentration by ELISA 
 
 
Standard curve used for the determination of epinephrine (EPI) concentrations in rat 
plasma.  Up-pointing triangle represents the actual measured concentration (5.6  
pg/mL) of a kit-provided low-concentration control (Control  1) with a range of 3.1-6.5 
pg/mL.  Down-pointing triangle represents the actual measured concentration (19.6 
pg/mL) of a kit-provided high-concentration control (Control 2) with a range of 13.4-26.1 
pg/mL.
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Figure 2.8 
 
Representative Standard Curve Used for Determination of Estradiol Concentrations by 
RIA 
 
 
Standard curve used for the determination of estradiol concentrations in rat plasma.  
Up-pointing triangle represents the actual measured concentration (12 pg/mL) of an 
extracted, kit-provided low-concentration control (Control 1) with a range of 10 ± 3 
pg/mL.               Down-pointing triangle represents the actual measured, concentration 
(34 pg/mL) of an     extracted,      kit-provided      high-concentration   control         
(Control 2) with a range of 30 ± 9 pg/mL.  
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Figure 2.9 
 
Representative Standard Curve Used for the  
Determination of cAMP Levels by EIA 
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Gene Primer Sequence (5’ to 3’) base pairs Cycle      #     Cycle Protocol    Temp       Time 
 
TH (+) ACATTTGAACTTAAAATTCAC (-) CGGGTGGTCCAGGTCCAGAT 263 29 
    94Po PC        0.5 min 
    55Po PC        0.5 min 
    72Po PC        1.0 min 
 
PNMT (+) CAGACTTCTTGGAGGTCAACCG (-) TTATTAGGTGCCACTTCGGGTG 610 30 
    94Po PC        0.5 min 
    55Po PC        0.5 min 
    72Po PC        1.0 min 
 
ERα (+) AATTCTGACAATCGACGCCAG (-) GTGCTTCAACATTCTCCCTCCTC 344 36 
    95Po PC        1.0 min 
    55Po PC        1.0 min 
    72Po PC        2.0 min 
 
ERβ (+) AAAGCCAAGAGAAACGGTGGGC (-) GCCAATCATGTGCACCAGTTCC 203 38 
    94Po PC        0.5 min 
    62Po PC        1.0 min 
    72Po PC        1.5 min 
β-
actin 
(+)TGGTGGGAATGGGTCAGAAGGACTC
(-) CATGGCTGGGGTGTTGAAGGTCTCA 265 26 
    94Po PC        1.0 min 
    63Po PC        1.0 min 
    72Po PC        1.0 min 
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Table 2.2 
 
PCR Primer Sequences and Protocols  
 
TH:  tyrosine hydroxylase; PNMT:  phenylethanolamine N-methyltransferase; ERα:  
estrogen receptor α; ERβ:  estrogen receptor β 
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Chapter 3:  Results 
 
A.  Estrogen Receptor Expression 
 In order for estradiol to affect adrenal medullary function via conventional steroid 
pathways, receptors for the steroid must be present in the tissue.   
RT-PCR analysis identified mRNA for both estrogen receptor α (ERα) and β (ERβ) in 
the adrenal medullary tissue of sham-operated controls (Figure 3.1; upper panel).  ERβ 
expression was more evident than ERα expression in the sham group.  The expression 
of both receptors in medulla was markedly lower than in uterine (ERα) and the ovarian 
(ERβ) tissue.  While the expression of ERα appeared to be increased by ovariectomy, 
densometric comparisons (Figure 3.1; lower panel) were not significant and estradiol 
replacement did not affect ERα expression in ovariectomized (OVEX) rats.  ERβ mRNA 
levels did not differ between ovariectomized and sham groups or estradiol-replaced and 
vehicle-treated OVEX groups. A limited number of immunoblot samples confirmed that 
ERα did translate to receptor protein in the medulla, but at a reduced level compared to 
expression in the uterus (Figure 3.2; upper panel).  Expression levels did not differ 
between vehicle-treated and estradiol-replaced OVEX groups (Figure 3.2; lower panel).  
Attempts to measure ERβ protein expression proved unsuccessful.   
 
B.  Effects of Physiological Concentrations of Estrogen  
1.  Effects of the Loss of Ovarian Steroids 
Experiment 1 compared the effects of insulin-induced hypoglycemia on plasma 
epinephrine concentration in 14-day OVEX and sham-operated rats. Pre-insulin plasma 
glucose concentration did not differ between the groups, and the glucose lowering 
effects of 0.25 U/kg insulin were identical in both groups at 30 (∆ -67 ± 2.3%) and 60 (∆ 
-36 ± 2.3%) minutes post-treatment (Figure 3.3; upper panel). Pre-insulin plasma 
epinephrine concentrations also did not differ between groups (150 ± 25 vs. 150 ± 26 
pg/mL).  However, 30 min of hypoglycemia increased plasma epinephrine concentration 
to a significantly greater extent (∆ +112%; P< 0.01) in the OVEX group compared to the 
sham-operated controls (Figure 3.3; lower panel). At 60 min post-insulin, plasma 
epinephrine concentrations were lower than at 30 min and did not differ between the 
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groups. Heart rate did not differ between the groups at any time point (Figure 3.4; upper 
panel).  Mean arterial blood pressure (MAP) was significantly decreased (P<0.001) to 
exactly the same extent after 30 min of hypoglycemia in the sham and OVEX groups (∆ 
-20 ± 4.0% and -21 ± 2.3% respectively) and remained depressed after 60 min (Figure 
3.4; lower panel).   
 
2.  Effects of Estradiol Replacement  
In order to assess the effects of estradiol per se in this response, experiment 2 
compared the effects of insulin-induced hypoglycemia on plasma epinephrine in 14-day 
OVEX and estradiol-replaced OVEX rats. For these experiments, one SILASTIC 
capsule containing either 17β-estradiol (E2) or sesame oil (vehicle) was implanted at 
the time of ovariectomy.  As described in the materials and methods section, this 
replacement paradigm produced plasma E2 concentrations that were almost identical to 
those seen in intact, late proestrous phase, female rats (20.0 ± 2.4 and 22.0 ± 2.5 pg/ml 
respectively).  Plasma E2 concentration in the OVEX animals (8.5 ± 0.6 pg/mL) was 
significantly lower than in both the intact and the E2-replaced OVEX rats (P<0.01).   
Pre-insulin plasma glucose concentrations did not differ between vehicle-treated 
and E2-treated OVEX rats (95 ± 3.4 and 103 ± 3.5, respectively) and were decreased to 
the same extent 30 min after insulin (∆ -64 ± 2.6%; Figure 3.5; upper panel).  Pre-insulin 
plasma epinephrine concentrations also did not differ between groups (133 ± 29 vs. 152 
± 30 pg/mL).  However, at 30 min post-insulin, the hypoglycemia-induced increase in 
plasma epinephrine concentration was significantly lower (∆ -56%; P< 0.001) in the 
OVEX +E2 group compared to the vehicle-treated OVEX (Figure 3.5; lower panel).  
Comparing across experiments, the increase in plasma epinephrine in the E2-replaced 
group was, in fact similar to that elicited in the SHAM group of experiment 1 (∆ 416 ± 75 
vs. 550 ± 73 pg/mL).  At 60 min post-insulin, plasma epinephrine concentrations again 
did not differ between groups despite the fact that plasma glucose was significantly 
lower in the OVEX compared to the OVEX +E2 group at this time point (61 ± 4.8 vs. 88 
± 9.0 mg/dL respectively; P<0.05).  Heart rate and MAP during hypoglycemia were 
similar to those seen in experiment 1.  Heart rate remained constant in both groups and 
was not different between groups at any time point (Figure 3.6; upper panel).  MAP 
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significantly decreased after 30 min of hypoglycemia in both groups (∆ -21 ± 2.5%  and 
-17 ± 2.4%, OVEX and OVEX +E2 respectively; P<0.001) and remained depressed 
after 60 min (Figure 3.6; lower panel), but was not different between groups at any time 
point.   
To this point, experiments demonstrate that physiological levels of E2 can 
suppress stress (hypoglycemia)-induced increases in plasma epinephrine.  
Theoretically, this could result from a steroid-mediated decrease in epinephrine 
secretion from the adrenal medulla and/or increase in the plasma clearance of 
epinephrine.  Measurement of epinephrine levels in blood collected directly from the 
adrenal vein was utilized as an index of epinephrine secretion.  Given the highly 
invasive nature of these studies, blood sampling was restricted to one 6 min period 
beginning 24 min post insulin, during a time of lowest plasma glucose.  Consistent with 
the plasma data, epinephrine secretion during this time period was significantly lower in 
the OVEX +E2 group compared to the OVEX (∆ -44%; P<0.005; Figure 3.7).  This E2-
mediated decrease in secretion could be due to several factors, including decreased 
epinephrine synthesis in the adrenal medulla, suppressed intracellular signaling for 
secretion in the chromaffin cells of the medulla, and/or decreased neural input to the 
medulla.   
Our data do not support the concept that E2 affects epinephrine biosynthesis.  
Using semi-quantitative RT-PCR,  mRNA expression levels for tyrosine hydroxylase 
(TH), the rate limiting enzyme in the catecholamine biosynthetic cascade, and for 
phenylethanolamine N-methyltransferase (PNMT), the enzyme necessary for the 
conversion of nor-epinephrine to epinephrine, did not differ between OVEX and sham or 
E2-replaced and vehicle-treated OVEX groups (Figure 3.8).  Similarly, protein 
expression of these enzymes measured by immunoblot also was not different in OVEX 
+E2 compared to OVEX rats (Figure 3.9). 
Isolated adrenal medullary chromaffin cells maintained in primary culture were 
used to assess the effects of E2 on agonist-induced increases in intracellular Ca P2+ P, 
which is the primary stimulus for epinephrine secretion. Exposure to 10 nM E2 for 48 hr 
had no significant effect on Ca P2+ P transients elicited by either 50 µM nicotine (NIC) or by 
60 mM KCl when compared to vehicle-treated control cells (Figure 3.10).  In contrast, 
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short-term treatment (3 min) with relatively high concentrations of E2 dose-dependently 
suppressed agonist-induced Ca P2+ P transients in chromaffin cells.  At 5 µM E2, NIC-
induced CaP2+ P transients were significantly suppressed by 33 ± 2.0% (P< 0.001; Figure 
3.11; upper panel); transients were almost completely abolished with exposure to 50 µM 
E2 (∆ -88 ± 4.2%; P<0.001). The suppressive effects of E2 were rapidly reversible. For 
example, exposure to 10 µM E2 inhibited NIC-induced responses by 48 ± 4.6% (P< 
0.001). Following removal of E2, the amplitude of the Ca P2+ P transient returned to 92 ± 
4.6% of control within 10 min (Figure 3.11; lower panel).  Increasing the time of 
exposure to E2 to 10 and 20 minutes had no additional inhibitory effect (Figure 3.12; 
upper panel). Ca P2+ P transients stimulated by KCl were inhibited 50% (P<0.001) by 3 min 
treatment with 50 µM E2 (Figure 3.12; lower panel).   
The effects of these two in vitro treatment paradigms were diametrically opposite 
in adrenal cortical cells compared to chromaffin cells.  Pituitary adenylate cyclase-
activating polypeptide-27 (PACAP-27; 100 nM)- induced increases in intracellular cAMP 
accumulation were significantly decreased in cells from a human adrenal cortical cell 
line (H295R) exposed to 10 nM E2 for 48 hr compared to vehicle-treated controls (∆ -
33%; P<0.05; Figure 3.13).  However, acute exposure to a supra-physiological 
concentration of E2 (50 µM) did not affect agonist-induced cAMP accumulation in this 
cell line (Figure 3.14).   
Subsequent experiments assessed the effects of E2 on renal sympathetic nerve 
activity (RSNA) as an index of neural input to the adrenal medulla.  As in previous 
experiments, insulin reduced plasma glucose concentrations to the same extent in both 
groups.  Hypoglycemia elicited a maximal increase in RSNA above baseline 
approximately 25 min after insulin in both groups and was significantly greater in the 
OVEX +E2 compared to the OVEX group (49 ± 6.0% vs 16 ± 1.8%; P< 0.01).  Activity 
returned toward baseline after peak, but remained significantly augmented above 
baseline for the duration of the experiment in the OVEX +E2 group.  However, in the 
OVEX group, RSNA had returned to baseline after 45 min of hypoglycemia, and was 
thereafter significantly decreased below baseline levels (Figure 3.15).    
To evaluate the effects of estradiol on epinephrine clearance, plasma 
epinephrine concentrations were compared in OVEX and OVEX +E2 rats before and 
 
 47
during infusion of three successively increasing doses of exogenous epinephrine.  Pre-
infusion plasma epinephrine concentrations did not differ between the groups (108 ± 19 
vs. 92 ± 9 pg/mL).  As anticipated, plasma epinephrine concentrations increased as the 
epinephrine infusion rate was increased in both groups.  These increases in plasma 
epinephrine levels were significantly lower in the E2-replaced OVEX animals (∆ -39% at 
30 min, ∆ -34% at 60 min, and ∆ -42% at 90 min; P<0.05; Figure 3.16), suggesting that 
the rate of epinephrine clearance is greater in this group compared to the OVEX group.   
 
C.  Effects of Supra-Physiological Concentrations of Estradiol 
Consistent with other reports, our work has demonstrated that acute exposure to 
high concentrations of estradiol can suppress agonist-induced Ca P2+ P transients in the 
chromaffin cell. Based on previous work from our laboratory (Wagner et al., 1999; 
Jorgensen et al., 2002), we would anticipate that this reduction in Ca P2+ P signaling would 
result in decreased epinephrine secretion.  Subsequently, experiments were designed 
to determine whether acute increases in circulating E2 can affect hypoglycemia-induced 
increases in plasma epinephrine.  The following modifications were applied to the basic 
hypoglycemia protocol for these experiments:  only ovariectomized rats were used and 
a bolus dose of E2 (150 µg/kg) or vehicle (10% EtOH) was intravenously infused over 2 
min 30 min prior to the insulin bolus. To maintain a high plasma concentration of free 
E2, rats were infused with either E2 or vehicle at a rate of 75 µg/kg/hr for the remainder 
of the experiment. 
Plasma glucose concentrations measured immediately prior to and 30 min after 
E2 or vehicle administration did not differ and the glucose lowering effects of insulin 
were identical in both groups at 30 and 60 min post-insulin (∆ -66 ± 1.6% and ∆ -35 ± 
3.1%; Figure 3.17; upper panel). Plasma epinephrine concentrations also did not differ 
prior to (82 ± 29.9 vs. 105 ± 16.5 pg/mL) or 30 min after (154 ± 23.0 vs. 203 ± 32.3 
pg/mL) E2 or vehicle administration.  E2 treatment significantly suppressed the rise in 
plasma epinephrine concentration after 30 min of hypoglycemia (∆ -34%; P< 0.05), and 
tended to suppress the rise at 60 min post-insulin (Figure 3.17; lower panel).  In contrast 
to experiment 1 and 2, heart rate did increase after 30 min in the E2-infused group, and 
after 60 min in the vehicle-infused group, but these increases did not reach significance 
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(P=0.06 and P=0.07 respectively; Figure 3.18; upper panel).  Also in contrast to 
experiments 1 and 2, MAP remained stable for the duration of the 60 min hypoglycemic 
test in both groups.  Neither heart rate nor MAP was different between the groups at 
any time point (Figure 3.18; lower panel). 
 
D.  Effects of Gender    
 Since the data to this point have established that both physiological and supra-
physiological levels of E2 can modulate stress-induced epinephrine responses, a final 
series of experiments compared hypoglycemia-induced increases in plasma 
epinephrine concentration in age-matched (14 week-old) male and female rats.  Plasma 
glucose concentration did not differ between the groups prior to insulin treatment (92 ± 
1.2 and 98 ± 3.3 mg/dL; male and female respectively).  The glucose lowering effects of 
insulin were identical in both groups (∆ -62 ± 2.2%) after 30 min of hypoglycemia.  
Plasma glucose levels were returned toward baseline after 60 min in both groups, but 
had returned to a greater degree in the female rats (73 ± 3.7 vs. 56 ± 3.7 mg/dL; P<0.01 
p) (Figure 3.19; upper panel). Pre-insulin plasma epinephrine concentrations were 
significantly higher in the female group compared to the male group (113 ± 6 vs. 79 ± 11 
pg/mL; P<0.05).  Hypoglycemia-induced increases in plasma epinephrine concentration 
were greater in the female group after 30 min (∆ + 308%; P<0.05) and did not differ 
after 60 min (Figure 3.19; lower panel), but heart rate was significantly increased above 
baseline after 30 min of hypoglycemia in the female group (∆ +10%; P<0.05).  Heart 
rate did not differ between the groups at any time point (Figure 3.20; upper panel).  
MAP significantly decreased over time in both groups, but also did not differ between 
groups (Figure 3.20; lower panel).  
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Figure 3.1 
 
Estrogen Receptor Gene Expression in the Adrenal Medulla 
 
 
Semi-quantitative RT-PCR analysis of adrenal medullary mRNA levels for estrogen 
receptor α (ERα) and estrogen receptor β (ERβ).  Tissue was collected 14 days after 
ovariectomy (OVEX), SHAM- surgery, ovariectomy + estradiol replacement (OVEX + 
E2) or + vehicle treatment (OVEX + VEH).  Upper Panel:  This ethidium bromide-
stained agarose gel illustrates each PCR product (n = 3 per group). The size of each 
product is listed in the left column.  Uterine (UT) tissue was used as a control for ERα 
expression, ovarian (OV) tissue was used as a control for ERβ expression; β-actin was 
used as an internal control for each reaction.   Lower Panel:  Densitometric analysis of 
the relative signal intensities. Columns (lower panel) represent Mean ± SEM of data 
from the 3 individual experiments in the upper panel. 
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Figure 3.2 
 
Estrogen Receptor α Protein Expression in the Adrenal Medulla 
 
 
Immunoblot analysis of adrenal medullary protein levels for estrogen receptor α (ERα).  
Tissue was collected 14 days after ovariectomy + vehicle (OVEX) or estradiol 
replacement (OVEX + E2). Upper Panel:  100 µg of adrenal medullary and 20 µg of 
uterine (UT) protein were separated by SDS-PAGE (n = 3 per group) and subjected to 
immunoblot analysis with rabbit anti ERα in a dilution of 1:2000 overnight.  The size of 
the product is listed in the left column.  Lower Panel:  Densitometric analysis of the 
relative signal intensities. Columns (lower panel) represent Mean ± SEM of data from 
the 3 individual experiments in the upper panel. 
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Figure 3.3 
 
Effect of Ovariectomy on Hypoglycemia-Induced Increases in Plasma Epinephrine 
Concentration 
 
 
Experiments were conducted 14 days after ovariectomy (OVEX) or sham-surgery 
(SHAM).  Insulin (0.25 U/kg) was administered intravenously as a bolus at time 0. 
Arterial blood samples (0.6 mL) were taken immediately prior to and 30 and 60 minutes 
after the insulin. Upper Panel: Effect of insulin on plasma glucose concentrations. Lower 
Panel: Effect of hypoglycemia on plasma epinephrine (EPI) concentrations.  Circles 
(upper panel) and columns (lower panel) represent Mean ± SEM of data from 7-8 
separate experiments.  * P < 0.01 compared to SHAM group. 
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Figure 3.4 
 
Effect of Ovariectomy on Hypoglycemia-Induced Changes in Heart Rate and Mean 
Arterial Blood Pressure 
 
 
Upper Panel: Effect of hypoglycemia on heart rate.  Lower Panel: Effect of 
hypoglycemia on mean arterial blood pressure (MAP).  Experiments were conducted 14 
days after ovariectomy (OVEX) or sham-surgery (SHAM).  Insulin was administered 
intravenously as a bolus at time 0.  Circles represent Mean ± SEM of data from 7-8 
separate experiments. 
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Figure 3.5 
 
Effect of Estradiol-Replacement in Ovariectomized Rats on Hypoglycemia-Induced 
Increases in Plasma Epinephrine Concentration 
 
 
Experiments were conducted 14 days after ovariectomy (OVEX); estradiol (E2)- or 
vehicle (sesame oil)-containing SILASTIC capsules were implanted at the time of 
surgery. Arterial blood samples (0.6 mL) were taken immediately prior to and 30 and 60 
minutes after the insulin. Upper Panel: Effect of insulin on plasma glucose 
concentrations. Lower Panel: Effect of hypoglycemia on plasma EPI concentrations.  
Circles (upper panel) and columns (lower panel) represent Mean ± SEM of data from 7-
8 separate experiments.  * P<0.001 compared to OVEX group. 
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Figure 3.6 
 
Effect of Estradiol-Replacement in Ovariectomized Rats on Hypoglycemia-Induced 
Changes in Heart Rate and Mean Arterial Blood Pressure 
 
 
Upper Panel: Effect of hypoglycemia on heart rate. Lower Panel: Effect of hypoglycemia 
on mean arterial blood pressure (MAP).  Experiments were conducted 14 days after 
ovariectomy (OVEX); estradiol (E2)- or vehicle (sesame oil)-containing SILASTIC 
capsules were implanted at the time of surgery.  Circles represent Mean ± SEM of data 
from 7-8 separate experiments. 
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Figure 3.7 
 
Effect of Estradiol-Replacement in Ovariectomized Rats on Hypoglycemia-Induced 
Increases in Adrenal Epinephrine Output  
 
Experiments were conducted 14 days after ovariectomy (OVEX); estradiol (E2)- or 
vehicle (sesame oil)-containing SILASTIC capsules were implanted at the time of 
surgery.  The left renal vein was isolated so that blood flow from the adrenal vein branch 
could be sampled.  Epinephrine (EPI) concentrations were measured in blood samples 
collected during one 6 min period starting 24 min after the insulin.  Columns represent 
Mean ± SEM of data from 4-5 separate experiments.  * P<0.005 compared to OVEX 
group. 
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Figure 3.8 
 
Effects of Ovariectomy and Estradiol-Replacement in Ovariectomized Rats on Adrenal 
Medullary Gene Expression of Catecholamine Biosynthetic Enzymes 
 
 
Adrenal medullary tyrosine hydroxylase (TH) and phenylethanolamine N-
methyltransferase (PNMT) mRNA expression analysis by semi-quantitative RT-PCR.  
Tissue was collected 14 days after ovariectomy (OVEX), SHAM- surgery, ovariectomy + 
estradiol replacement (OVEX +E2) or + vehicle treatment (OVEX +VEH).  Upper Panel:  
Ethidium bromide-stained agarose gel illustrating each PCR product (n = 3 per group). 
The size of each product is listed in the left column. Lower Panel:  Densitometric 
analysis of the relative signal intensities. Columns (lower panel) represent Mean ± SEM 
of data from the 3 individual experiments in the upper panel. 
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Figure 3.9 
 
Effect of Estradiol-Replacement in Ovariectomized Rats on Adrenal Medullary Protein 
Expression of Catecholamine Biosynthetic Enzymes 
 
 
Immunoblot analysis of adrenal medullary protein levels for tyrosine hydroxylase (TH) 
and phenylethanolamine N-methyltransferase (PNMT).  Tissue was collected 14 days 
after ovariectomy (OVEX); estradiol (E2)- or vehicle (sesame oil)-containing SILASTIC 
capsules were implanted at the time of surgery.  Upper Panel:  20 µg of adrenal 
medullary protein samples were separated by SDS-PAGE (n = 3 per group) and 
subjected to immunoblot analysis with rabbit anti TH or rabbit anti PNMT in a dilution of 
1:1000 for 1 hr.  The size of the product is listed in the left column.  Lower Panel:  
Densitometric analysis of the relative signal intensities. Columns (lower panel) represent 
Mean ± SEM of data from the 3 individual experiments in the upper panel. 
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Figure 3.10 
 
Effect of 48 hr Estradiol Treatment on Basal and Agonist-Induced Ca2+ Transients in 
Rat Chromaffin Cells 
 
 
Cells were exposed to either vehicle or 10 nM estradiol (E2) for 48 hr prior to analysis.  
Data are expressed as peak intracellular Ca2+ concentration achieved in response to 
either 50 µM nicotine (NIC) or to 60 mM KCl.  Columns represent Mean ± SEM of data 
from 3 separate isolations. 
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Figure 3.11 
 
Effect of Acute Estradiol Treatment on Agonist-Induced Ca2+ Transients in Rat 
Chromaffin Cells:  Dose Dependent Effects and Representative Trace 
 
 
Upper Panel: Dose-dependent effects of acute estradiol (E2) exposure on nicotine 
(NIC)-induced intracellular Ca2+ transients in rat chromaffin cells. Cells were exposed to 
various concentrations of E2 for 3 min prior to stimulation with a 15-sec pulse of 50 µM 
NIC.  Data are expressed as a percent of a control NIC-induced Ca2+ transient 
measured prior to E2 treatment. Lower Panel:  Representative trace of intracellular Ca2+ 
responses to 15-sec pulses of 50 µM NIC (arrows) prior to E2 exposure, after 3 min 
exposure to 10 µM E2, and after 10 min washout of E2.  Columns (upper panel) 
represent Mean ± SEM of data from 3-4 separate isolations.  * P<0.001 compared to 
control transients 
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Figure 3.12 
 
Effect of Acute Estradiol Treatment on Agonist-Induced Ca2+ Transients in  
Rat Chromaffin Cells:  Time Dependent Effects and  
Nicotine vs KCl-Induced Transients 
 
 
Upper Panel:  Time dependent effects of acute estradiol (E2) exposure on nicotine 
(NIC)-induced intracellular Ca2+ transients in rat chromaffin cells. Cells were exposed to 
either 1 or 10 µM concentrations of E2 for 3, 10, and 20 min prior to stimulation with a 
15-sec pulse of 50 µM NIC.  Data are expressed as a percent of a control NIC-induced 
Ca2+ transient measured prior to E2 treatment. Lower Panel:  Effect of acute E2 
exposure on NIC- and KCl-induced intracellular Ca2+ transients in rat chromaffin cells. 
Cells were exposed to either 10 or 50 µM concentrations of E2 for 3 min prior to 
stimulation with a 15-sec pulse of 50 µM NIC or 60 mM KCl.  Columns represent Mean 
± SEM of data from 3-4 separate isolations.  * P<0.001 compared to control transients. 
 72
 
 73
BASAL PAC 27
cA
M
P 
(f
m
ol
/ µ
g 
pr
ot
ei
n)
0
20
40
60
80
VEHICLE
48 HR E2
*
 
 
Figure 3.13 
 
Effect of 48 hr Estradiol Treatment on Basal and Agonist-Induced cAMP Accumulation 
in H295R Cells 
 
 
Cells were exposed to either vehicle or 10 nM estradiol (E2) for 48 hr prior to incubation 
(10 min) with PACAP-27 (PAC 27; 10-7 M).  All incubations included the 
phosphodiesterase inhibitor Ro20-1724 (25 µM).  Columns represent Mean ± SEM of 
duplicate determinations from 3 experiments. * P<0.05 compared to vehicle-treated 
cells. 
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Figure 3.14 
 
Effect of Acute Estradiol Treatment on Basal and Agonist-Induced cAMP Accumulation 
in H295R Cells 
 
 
Cells were exposed to either vehicle or 10 nM estradiol (E2) for 10 min prior to 
incubation (10 min) with PACAP-27 (PAC 27; 10-7 M).  All incubations included the 
phosphodiesterase inhibitor Ro20-1724 (25 µM).  Columns represent Mean ± SEM of 
duplicate determinations from 3 experiments. 
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Figure 3.15 
 
Effect of Estradiol-Replacement in Ovariectomized Rats on Hypoglycemia-Induced 
Changes in Renal Sympathetic Nerve Activity 
 
 
Experiments were conducted 14 days after ovariectomy (OVEX); estradiol (E2)- or 
vehicle (sesame oil)-containing SILASTIC capsules were implanted at the time of 
surgery.  A renal sympathetic nerve fiber was isolated and placed on a stainless steel 
electrode and stabilized with a silicon-based impression material.  Renal sympathetic 
nerve activity (RSNA) was recorded for 20 min prior to insulin to calculate baseline 
activity.  Data are expressed as a percent of the baseline shown as the solid line at 
100%.  Circles represent Mean ± SEM of data from 3 separate experiments.  * P<0.05 
compared to OVEX group. Ψ P< 0.05 compared to baseline. 
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Figure 3.16 
 
Effect of Estradiol-Replacement in Ovariectomized Rats on  
Plasma Epinephrine Clearance Rates 
 
 
Plasma epinephrine (EPI) concentrations before and during EPI infusions at a rate of  
600, 1500, and 3000 pmol/kg/min (arrows).  An arterial blood sample (0.6 mL) was 
taken prior to the start of the infusion and after 30 min of infusion with each dose.  
Experiments were conducted 14 days after ovariectomy (OVEX); estradiol (E2)- or 
vehicle (sesame oil)-containing SILASTIC capsules were implanted at the time of 
surgery.  Circles represent Mean ± SEM of data from 4-5 separate experiments. 
*P<0.05 compared to OVEX group. 
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Figure 3.17 
 
Effect of Acute Estradiol Treatment in Ovariectomized Rats on Hypoglycemia-Induced 
Increases Plasma Epinephrine Concentration 
 
 
Experiments were conducted 14 days after ovariectomy.  17β-Estradiol (E2; 150 µg/kg) 
was administered IV over a 2 min period 30 min prior to insulin, followed by a constant 
infusion (75 µg/kg/hr) for the duration of the experiment.  Insulin (0.25 U/kg) was 
administered intravenously as a bolus at time 0. Arterial blood samples (0.6 mL) were 
taken immediately prior to and 30 and 60 minutes after the insulin. Upper Panel: Effect 
of insulin on plasma glucose concentrations. Lower Panel: Effect of hypoglycemia on 
plasma epinephrine (EPI) concentrations.  Circles (upper panel) and columns (lower 
panel) represent Mean ± SEM of data from 6-7 separate experiments.  * P< 0.01 
compared to vehicle-treated group. 
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Figure 3.18 
 
Effect of Acute Estradiol Treatment in Ovariectomized Rats on Hypoglycemia-Induced 
Changes in Heart Rate and Mean Arterial Blood Pressure 
 
 
Upper Panel: Effect of hypoglycemia on heart rate. Lower Panel: Effect of hypoglycemia 
on mean arterial blood pressure (MAP).  Experiments were conducted 14 days after 
ovariectomy.  17β-Estradiol (E2) or vehicle was administered IV over a 2 min period 30 
min prior to insulin, followed by a constant infusion of the steroid for the duration of the 
experiment.  Insulin was administered intravenously as a bolus at time 0. Circles 
represent Mean ± SEM of data from 6-7 separate experiments.  
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Figure 3.19 
 
Effect of Gender on Hypoglycemia-Induced Increases in  
Plasma Epinephrine Concentration 
 
 
Experiments were conducted in 14 week-old male and female rats.  Insulin (0.25 U/kg) 
was administered intravenously as a bolus at time 0. Arterial blood samples (0.6 mL) 
were taken immediately prior to and 30 and 60 minutes after the insulin. Upper Panel: 
Effect of insulin on plasma glucose concentrations. Lower Panel: Effect of hypoglycemia 
on plasma epinephrine (EPI) concentrations.  Circles (upper panel) and columns (lower 
panel) represent Mean ± SEM of data from 6-7 separate experiments.  * P < 0.01 
compared to male group. 
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Figure 3.20 
 
Effect of Gender on Hypoglycemia-Induced Changes in  
Heart Rate and Mean Arterial Blood Pressure 
 
 
Upper Panel: Effect of hypoglycemia on heart rate. Lower Panel: Effect of hypoglycemia 
on mean arterial blood pressure (MAP). Experiments were conducted in 14 week-old 
male and female rats. Insulin was administered intravenously as a bolus at time 0. 
Circles represent Mean ± SEM of data from 6-7 separate experiments.  
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Chapter 4: Discussion 
 
Effects of Estradiol 
A number of clinical studies have reported that stress-induced increases in 
plasma epinephrine levels are decreased in post-menopausal subjects receiving 
estrogen-replacement therapies (Del Rio et al., 1993; Komesaroff et al., 1999; Ceresinsi 
et al., 2000; Sandoval et al., 2003).  Estrogen supplementation even attenuates mental 
stress-induced increases in plasma epinephrine in hypoganadal, elderly men 
(Komesaroff et al., 2002).  While these data illustrate that administration of exogenous 
estradiol suppresses the adrenal medullary response to stress, it remains to be 
established whether normal circulating levels of estradiol can modulate this response, 
due to the fact that the levels and types of estrogen administered in these replacement 
therapies were typically non-physiologic and were almost always administered orally.  
Also, these reports were limited to a cohort of aging subjects, and most often investigate 
the effect of replacement therapies in women whose circulating estradiol concentrations 
have been severely depleted for months or even years.  In this context, the timing of 
estradiol replacement after the loss of the steroid (by ovariectomy) can affect final 
outcomes.  For example, the ovariectomy-induced rise in circulating luteinizing hormone 
(LH) level in rats is abolished by estradiol replacement at the time of ovariectomy, while 
estradiol replacement three weeks after ovariectomy reduces the serum LH level by 
only 50% (King et al., 1987).  The same study also reported that luteinizing hormone-
releasing hormone quantities in the medial basal hypothalamus are higher in 
ovariectomized rats administered estradiol replacement at the time of surgery, 
compared to rats that were estradiol replaced three weeks after ovariectomy.  In order 
to avoid these confounds, the primary goal of the present study was to assess the 
adrenal medullary response to stress in young, but sexually mature rats in which 
estradiol levels were controlled by ovariectomy and immediate estradiol replacement.   
Our studies have established that physiological circulating levels of 17β-estradiol 
suppress stress-induced increases in plasma epinephrine in the young adult, female rat. 
This conclusion is based on two fundamental observations. First, insulin-induced 
hypoglycemia increases plasma epinephrine concentration to a significantly greater 
 
extent in 14-day ovariectomized rats than in sham-operated controls. Second, and 
perhaps more specifically, the rise in plasma epinephrine is significantly lower in 
ovariectomized, estradiol-replaced rats than in vehicle-treated ovariectomized rats.  This 
replacement regime elicited plasma estradiol concentrations virtually identical to those 
of sham-operated rats during the pro-estrous phase of the estrus cycle.  Comparing 
across groups, the rise in plasma epinephrine attained with 30 min of hypoglycemia in 
the estradiol-replaced rats was, in fact, quite comparable to that of the sham-operated 
controls, suggesting indirectly that the modulation of plasma catecholamine levels is 
due to an effect of physiological levels of circulating estradiol alone and not in 
combination with other ovarian steroids. 
Insulin-induced hypoglycemia is a standard method used for assessing adrenal 
stress responses, despite the fact that the mechanism by which insulin elicits an 
increase in plasma catecholamines is still not completely understood.  While there is 
evidence that insulin can directly stimulate epinephrine release from the adrenal 
medulla in vitro (Macho et al., 1996), the preponderance of evidence suggests that the 
in vivo response requires a centrally-mediated neuronal activation.  For example, it has 
been shown that adrenal denervation inhibits the hypoglycemia-induced increases in 
both plasma epinephrine concentration (Khalil et al., 1986) and adrenal medullary 
tyrosine hydroxylase gene expression (Vietor et al., 1996).  Increases in plasma 
epinephrine are also attenuated in brain/neuron specific insulin receptor knockout mice 
(Fisher et al., 2005).   
Despite this uncertainty surrounding the mechanism, there are several 
advantages in utilizing an insulin-induced hypoglycemic model of stress.  Firstly, it is 
well established that hypoglycemia consistently increases plasma epinephrine levels in 
both experimental animals (Fujino and Fujii, 1995; Vollmer et al., 1997; Drake et al., 
1998) and humans (Diamond et al., 1993; Davis et al., 2000; Sandoval et al., 2003; 
Heise et al., 2004).  Secondly, in contrast to other stress paradigms such as footshock 
(Weinstock et al., 1998), hypoxia (Bloom et al., 1977), and cold (Kanayama et al., 
1999), the magnitude of the epinephrine increase in response to hypoglycemia is insulin 
dose-dependent. A third advantage of this model is that it can be utilized reliably in both 
conscious (Goldstein et al., 1993; Vollmer et al., 1997; Batista et al., 2005; Fisher et al., 
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2005) and anesthetized (Mokuda and Sakamoto, 1994; Lamarche et al., 1995; Drake et 
al., 1998) experimental animals.  We selected the anesthetized model for use in the 
present studies for a number of reasons.  For example, anesthesia decreases many of 
the environmental confounds that can affect the stress response.  Second, this model 
eliminates the need for multiple survival surgeries.  Finally, from a productivity 
perspective, the turnover rate of chronically instrumented, conscious animal studies is 
much slower than that of anesthetized studies.  
 The utilization of an anesthetized model in these studies was, however, also 
precipitated by our early work which focused on the development of a classical 
conditioning paradigm so that stress responses in the conscious female rat could be 
assessed.  Using a paradigm modified from Randall et al. (1994), rats were first 
habituated to handling and restraint in a cloth sock for 1-2 days, after which each rat 
was exposed for 1 week to 5 trials per day of a 15-second pulsed tone followed by a 0.5 
second, 0.4 mAmp tail shock.  On the day of the experiment, the rats were placed in the 
sock and exposed to 1 tone + shock.  This paradigm has been shown to evoke 
immediate, short-duration increases in sympathetic nerve activity (Randall et al., 1994; 
Brown et al., 1999) and in principle, should have resulted in epinephrine secretion from 
the adrenal medulla.  However, this paradigm failed to elicit even marginal increases in 
plasma epinephrine levels, suggesting that the adrenal medulla does not secrete 
epinephrine in response to this model of stress. 
The estrogen-dependent suppression of hypoglycemia-induced increases in 
plasma epinephrine could, in theory, be due to either decreased adrenal medullary 
secretion and/or increased peripheral clearance of epinephrine.  We do have data to 
support the concept that estradiol replacement suppresses adrenal medullary secretion 
in ovariectomized rats.  This conclusion is based on measurements of epinephrine 
concentration from the adrenal vein during hypoglycemia.  Our approach in these 
experiments was a modification of a standard method used to assess adrenal 
catecholamine output (Engeland and Gann, 1989; Gaumann et al., 1990; Vollmer et al., 
2000; Lamouche and Yamaguchi, 2001), which allows blood to flow from the vein for 
the duration of the experiment while donor blood is infused through a peripheral vein. In 
order to minimize confounds associated with continuous bleeding and donor 
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replacement, blood was collected over just one 6 min period after 24 min of 
hypoglycemia in the present study.  The epinephrine measured during this time should 
represent peak adrenal output because both the hypoglycemia-induced decrease in 
blood glucose concentration and rise in sympathetic nerve activity are maximal at this 
time. Ideally, to confirm this assumption these experiments should be repeated to allow 
sampling at other post-insulin time points as well as to establish pre-insulin epinephrine 
secretory levels.  Recognizing the inherent limitations of this approach, considerable 
time was initially invested on attempting to establish a method for the continuous 
measurement of adrenal epinephrine output using in vivo chronoamperometry.  This 
technique successfully detects and quantifies catecholamines in the brain (Freund et al., 
2003; Moxon et al., 2004; Burmeister et al., 2005; Glaser et al., 2005).  With assistance 
from Dr. Greg Gerhardt and members of his laboratory, both a Nafion-coated carbon 
fiber electrode and a ceramic-based multisite electrode were successfully introduced 
into the adrenal vein and the adrenal medulla.  However, both electrodes failed to detect 
epinephrine at either site, due, at least in part, to the electrodes’ inability to oxidize 
catecholamines in blood or highly vascularized tissue.   
Subsequent experiments addressed the question of whether estradiol-dependent 
suppression of the adrenal output of epinephrine was due to decreased synthesis 
and/or secretion of epinephrine by the chromaffin cell.  Green et al. (1999), initially 
reported estrogen receptor-α (ERα) immunoreactivity in chromaffin cells of the female 
but not male rat adrenal gland.  The RT-PCR and immunoblot data in the present study 
confirms and expands on this report, since ER-α message and protein expression and 
estrogen receptor-β (ERβ) message can be detected in the female rat adrenal medulla, 
albeit at considerably lower levels of expression than in the uterus and ovary 
respectively.   
Despite the probable existence of functional estradiol receptors in the medulla, 
the present studies do not support the hypothesis that this steroid directly affects either 
epinephrine biosynthesis in or secretion from the adrenal medulla.  At the gene level, 
semi-quantitative RT-PCR analysis revealed that mRNA levels for both tyrosine 
hydroxylase (TH) and phenylethanolamine N-methytransferase (PNMT) are not different 
in adrenal medullae taken from ovariectomized versus sham-operated animals or from 
 
estradiol- versus vehicle-replaced ovariectomized rats. At the protein level, neither TH 
nor PNMT expression was modulated by estradiol treatment in ovariectomized rats. 
There are, in fact, already a number of contradictory reports on the effects of 
estradiol on catecholamine biosynthesis in the adrenal medulla.  Recently, Serova et al. 
(2005) have reported that TH mRNA levels are increased in ovariectomized rats treated 
with estradiol benzoate for 16 days compared to vehicle-treated ovariectomized rats.  
And while  Kohler et al. (1975) have reported that 10 days of estrogen administration to 
intact female rats increases TH activity, de Miguel et al. (1989) have reported that TH 
activity is unaffected by estrogen treatment in ovariectomized rats.  Additionally, it has 
also been reported that TH activity is not different in the adrenal medulla of aged (22 
months old) female rats compared to young (2 months old), but adrenal medullary 
epinephrine content is greater in the aged rats (Fernandez-Ruiz et al., 1989).   
With regard to secretion, acetylcholine released by the adrenal nerve stimulates 
Na+ influx via nicotinic acetylcholine receptor-operated ion channels on the chromaffin cell 
(Wada et al., 1985).  The resultant depolarization activates voltage-gated Ca2+ channels 
and results in a transient rise in intracellular free Ca2+ concentration, which is the primary 
trigger for catecholamine exocytosis (Kilpatrick et al., 1982).  Previous studies from our 
laboratory established that 48 hr exposure to the synthetic glucocorticoid 
dexamethasone significantly potentiated agonist-induced intracellular Ca2+ transients in 
isolated adrenal medullary chromaffin cells (Fuller et al., 1997a, b).  In the present study, 
48 hr exposure to a relatively physiologic concentration of estradiol (10 nM) had no 
significant effect on nicotine-induced intracellular Ca2+ transients, suggesting, albeit 
indirectly, that the effects of estradiol in vivo are not due to a suppression of agonist-
induced Ca2+ signaling in, and as a consequence epinephrine secretion from, the 
chromaffin cell.  
While nicotinic acetylcholine receptor mediated Ca2+ signaling is the primary 
stimulatory pathway in these cells, it is well-established that chromaffin cells also express 
muscarinic acetylcholine receptors (Inoue and Kuriyama, 1991; Inoue and Imanaga, 
1995), which, upon activation, can also directly stimulate catecholamine secretion from rat 
the chromaffin cell (Finnegan et al., 1996).  There is evidence that the number of 
muscarinic acetylcholine receptors is increased in the hippocampus of ovariectomized 
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rats, and that this increase is abolished by estradiol treatment (Cardoso et al.; 2004), 
therefore future studies should also investigate the effects of estradiol on muscarinic-
receptor mediated contributions to secretion.     
 Although adrenal output and intracellular Ca2+ signaling are valid means by which 
to assess stress-induced chromaffin cell secretion, cellular processes ‘downstream’ of 
Ca2+ signaling were not directly examined in these studies.  Previous studies from our 
laboratory have determined nicotinic-induced catecholamine secretion in single cells by 
carbon-fiber amperometry (Liu et al., 2001).  One of the limitations of this approach is that 
measurements can reliably only be compared within the same cell, making this technique 
more appropriate for acute drug exposure studies.  The effects of longer-term (ie. 48 hr) 
exposure to a steroid (dexamethasone) on agonist-induced epinephrine secretion have 
been assessed in populations of cells by HPLC (Fuller et al., 1997b), but this method 
requires a large number of cells for each experiment and cell yields from rat adrenal 
glands are typically too low for this type of analysis.  However, while chronoamperometry 
has not proven effective for measuring plasma concentrations of epinephrine, it may be 
possible to utilize this approach to assess the effects of estradiol on secretion in vitro.  Our 
in vivo attempts at chronoamperometry gave us experience in calibrating carbon-fiber 
electrodes for epinephrine in solution and it may be possible to use these types of 
electrodes in order to measure secretion from a small number of cells.  
A more global approach to examine the effects of estradiol on stimulus-secretion 
coupling pathways in the adrenal medulla would be to utilize gene array technology.  
However, our experience in this area was not very encouraging.  In experiments to assess 
the effects of age on gene expression in the adrenal medulla, the expression levels of 62 
known genes were significantly increased and the expression levels of 67 known genes 
were significantly decreased by a minimum of 1.5 fold in the adrenal medulla of aged 
compared to young rats.  However, none of the genes that were affected by age were 
known to be particularly important in secretory signaling or biosynthetic pathways, even 
though it is well established that both stress-induced plasma catecholamine levels 
(McCarty 1986; Mabry et al., 1995) and expression of tyrosine hydroxylase (Voogt et al., 
1990; Tumer et al., 1992; 1997; Tumer and Larohelle, 1995) are significantly increased 
with age.  
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In contrast to the apparent lack of effect of circulating levels of estradiol on 
chromaffin cell function discussed earlier, short-term exposure to high, presumably non-
physiologic levels of estradiol can suppress agonist-induced Ca P2+ P signaling in the 
chromaffin cell. These data are fundamentally consistent with several previous reports 
in which acute exposure to micromolar concentrations of estradiol significantly 
depressed nicotinic receptor-triggered increases in intracellular Ca P2+ P concentration in 
bovine chromaffin cells (Liu et al., 2002; Machado et al., 2002) and KCl-induced 
transients in PC-12 cells (Kim et al., 2000).  The present study demonstrated that 3 min 
of exposure to estradiol is sufficient to dose-dependently suppress nicotine and KCl-
induced CaP2+ P transients in rat chromaffin cells.  The fact that the effect was both rapid 
and reversible suggests that estradiol is acting non-genomically.  Although 
catecholamine secretion was not measured in this study, previous work from our 
laboratory has shown that a suppression of nicotine-induced intracellular Ca P2+ P transients 
of this magnitude reduces nicotine-induced catecholamine secretion from porcine 
chromaffin cells (Wagner et al., 1999).  However, it has been reported that short-term 
exposure to estrogens, including 17β-estradiol, has no effect on acetylcholine-induced 
secretion from bovine chromaffin cells, while androgens inhibit agonist-induced 
secretion (Dar and Zinder, 1997).      
Due to the high concentrations of estradiol used, it is plausible that the acute 
effects of estradiol on chromaffin cell signaling are non-cell specific.  The present study 
has demonstrated that acute exposure to a high concentration of estradiol does not 
affect function in every adrenal cell type. The NCI-H295R cell line was derived from 
human adrenocortical cells.  These cells retain the ability to secrete mineralocorticoids, 
glucocorticoids, and adrenal androgens (Rainey et al., 1994), and like primary adrenal 
cortical cells, express pituitary adenylate cyclase-activating polypeptide (PACAP) 
receptors that, when activated, stimulate cAMP synthesis and the subsequent release 
of aldosterone and/or cortisol (Bodart et al., 1997; Haidan et al., 1998).   Acute 
exposure to a high concentration of estradiol did not affect PACAP-mediated cAMP 
accumulation in these cells.  In contrast, 48 hr exposure to a physiologic concentration 
of estradiol significantly attenuated PACAP-induced increases in cAMP accumulation in 
this cell line.  While it is difficult to correlate data between primary cultures of cells and a 
 
cell line, as well as between species, these data do suggest that both the acute and 
long-term effects of estradiol on intracellular signaling processes are cell-type specific. 
Given that acute treatment with estradiol attenuated agonist-induced Ca2+ 
transients in the chromaffin cell, epinephrine secretion should also be suppressed, 
which would result in decreased stress-induced rises in plasma epinephrine levels in 
vivo.  Using the hypoglycemic stress model, we tested this hypothesis and have now 
shown that an acute infusion of supra-physiological levels of estradiol does suppress 
the insulin-induced rise in plasma epinephrine in ovariectomized rats. It should be noted 
however, that the overall effect on plasma epinephrine levels is relatively small given 
the large increase in plasma estradiol levels that occurred with this infusion paradigm. 
Therefore, it is unlikely that a physiological increase in estradiol could occur that would 
be of the magnitude needed to elicit an acute effect on circulating epinephrine levels. 
The studies to this point do not support the concept that the estradiol-dependent 
suppression of stress-induced adrenal epinephrine output is due to modulation of either 
epinephrine biosynthesis or stimulus-secretion coupling in the chromaffin cell.  
Therefore, subsequent experiments addressed the possibility that estradiol can 
modulate stress-induced increases in sympathetic nerve activity, which is the initial 
trigger for catecholamine secretion from the adrenal medulla. Although previous reports 
have demonstrated that intravenous administration of supra-physiologic concentrations of 
estrogen can rapidly suppress both renal and splanchnic nerve activity in ovariectomized 
rats (He et al., 1998), and that chronic estrogen treatment can affect sympathetically-
mediated baroreflex sensitivity (He et al., 1999; Pamidimukkala et al., 2003),  in the 
present study, hypoglycemia-induced increases in nerve activity were actually greater in 
the estradiol-replaced ovariectomized rats compared to vehicle-treated ovariectomized 
rats.  Clearly these data are not consistent with the concept that estradiol suppresses 
epinephrine secretion by modulating neural input, since this increased nerve activity 
should elicit a greater epinephrine response to stress.   
One limitation of these data is that recordings were made from the more easily 
accessible renal nerve, while secretion is predominately regulated by the activity of the 
splanchnic/adrenal nerve.  Therefore, the activity of these nerves during hypoglycemia 
should also be examined in order to fully assess the effect of estradiol on neural input to 
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the adrenal medulla.  This requirement is further supported by the fact that a given 
stimulus can induce a diverse pattern of sympathetic responses.  For example, Scislo et 
al. (2001) demonstrated that stimulation of A2A receptors increased adrenal nerve activity, 
decreased renal nerve activity, and did not affect lumbar nerve activity.  This same group 
also reported that A1 receptor stimulation increased the activity of the adrenal, renal, and 
lumbar nerves, but the magnitude of the increase was greatest in the adrenal nerve and 
lowest in the lumbar nerve.  In addition, it has been reported that estrogen potentiates 
presynaptic function in cultured hippocampal neurons (Yokomaku et al., 2003) and 
enhances glutamate receptor-mediated excitatory postsynaptic potential (Foy et al., 1999); 
but there is little published research investigating the effects of physiological 
concentrations of estradiol on nerve properties such as conductivity, pre- and post-
synaptic function and synapse plasticity.  The information from such studies would 
certainly offer insight into how estrogen may modulate the neural input to the adrenal 
medulla.     
In review of the results thus far, the reduced adrenal output of epinephrine in 
estradiol-replaced, ovariectomized rats is consistent with the observed depressive 
effects of physiological levels of estradiol on the hypoglycemia-induced increases in 
plasma epinephrine concentration.  The mechanism(s) underlying the suppressive 
effects of estradiol on adrenal medullary secretion remain to be defined.  A final series 
of experiments assessed whether the difference in plasma epinephrine concentration 
during hypoglycemia may also be attributed to differential rates of plasma 
catecholamine clearance.  To assess the effects of estradiol on plasma epinephrine 
handling, 30 min sequential intravenous infusions of epinephrine (600, 1500, and 3000 
pmol/kg/min) were administered in vehicle and estradiol-treated ovariectomized rats.  At 
all epinephrine infusion rates, plasma epinephrine concentrations were lower in the 
estradiol-replaced ovariectomized group compared to the vehicle-treated 
ovariectomized rats after each infusion, suggesting that the clearance of epinephrine 
from the circulation was higher in these animals.    
However, these data are not consistent with the majority of available information 
which suggests that estrogen negatively regulates both catecholamine metabolism and 
cellular reuptake.  For example, the activity of catechol-O-methyltransferase (COMT), 
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the main enzyme responsible for the metabolism of catecholamines, is at its lowest level 
in the female rat brain and adrenal gland during the pro-estrous phase of the estrous 
cycle (Parvez et al., 1978), the period of highest circulating estradiol concentration 
(Smith et al., 1975).  Also, both the gene expression and the activity of COMT are 
down-regulated by physiologic concentrations of estradiol in MCF-7 cells (Xie et al., 
1999; Jiang et al., 2003).  It has also been reported that estradiol can affect nor-
epinephrine transporter function in bovine chromaffin cells, suppressing cellular 
reuptake (Toyohira et al., 2003).  Consequently, these effects on metabolism and 
reuptake should elevate plasma epinephrine levels. 
 
Effects of Gender 
 As noted earlier in the discussion, estradiol supplementation can also reduce the 
epinephrine response to stress in men (Komesaroff et al., 2002).  These data are 
consistent with both clinical (Diamond et al., 1993; Davis et al., 2000; Galassetti et al., 
2001) and basic science (Drake et al., 1998) studies which have demonstrated that 
stress-induced increases in plasma catecholamines are lower in females than in males.  
In contrast, however, the data from our experiments on gender are diametrically 
opposed to these reported observations, since hypoglycemia-induced increases in 
plasma epinephrine levels are greater in female rats compared to age-matched males.  
Our data are, however, consistent with at least one published report, which 
demonstrated that the extent and duration of both the corticosterone and epinephrine 
response to foot-shock is also higher in females compared to age-matched males 
(Weinstock et al, 1998). 
 
Summary 
The studies contained in this dissertation have clearly demonstrated that 
physiological circulating levels of estradiol suppress stress-induced increases in plasma 
epinephrine concentration.  This suppression may be due to both a reduction in adrenal 
medullary epinephrine secretion and an increase in plasma clearance of the 
catecholamine.  However, the specific mechanism(s) underlying these effects have yet 
to be established.  For example, while the decreased adrenal vein epinephrine 
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concentration is consistent with a reduction in epinephrine secretion, our data suggest 
that this effect could not be attributed to decreased biosynthesis, attenuation of 
intracellular Ca2+ signaling, or decreased sympathetic nerve activity.  Additionally, while 
epinephrine clearance is markedly increased in estradiol-replaced rats, available data in 
the literature do not support that this increase could be attributed to the increased 
activity of catecholamine metabolizing enzymes such as COMT.     We have also 
confirmed previous in vitro reports that short-term exposure to high concentrations of 
estradiol can attenuate agonist-induced Ca2+ signaling in the chromaffin cell and shown 
for the first time that acute exposure to high, presumably non-physiological, levels of 
estradiol can suppress stress-induced increases in plasma epinephrine in vivo.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Julye M. Adams 2005 
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